Introduction: Although BTK inhibitors (BTKi) are effective therapeutics in the treatment of B cell malignancies, emerging BTK resistance mutations in chronic lymphocytic leukemia (CLL), as well as potential growth-promoting kinase-independent scaffolding function of BTK, present a need for improved or new approaches. Additionally, preclinical and clinical data in non-Hodgkin's lymphoma (NHL) suggest that drugs modulating cereblon may synergize with BTKi to provide a therapeutic effect. NX-2127 is an oral, first-in-class, dual-function small molecule degrader that combines BTK degradation with the immunomodulatory activity of an
Ikaros and Aiolos degrader. Preliminary safety of NX-2127 in patients across B cell malignancies and efficacy in patients with CLL have been presented previously [Mato et al. 2022; Danilov et al. 2023]. Here we report further safety and efficacy follow-up in patients with CLL and efficacy data in patients with NHL enrolled to date.

Methods: NX-2127-001 (NCT04830137) is a first-in-human, multicenter, open-label, dose-escalation (Phase 1a) and cohort-expansion (Phase 1b) trial evaluating the safety and preliminary efficacy of NX-2127 in adults with relapsed/refractory B cell malignancies, including CLL, diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), and Waldenstrom’s macroglobulinemia (WM). NX-2127 is administered orally once daily in 28-day cycles.

Results: As of 9 June 2023, 47 patients were enrolled and treated with NX-2127 at once-daily doses of 100 mg (n=28), 200 mg (n=10), and 300 mg (n=9). Patients were predominantly male (66%), with a median age of 74 (range 50–92) years. Twenty-nine patients were treated for CLL/small lymphocytic lymphoma, 5 DLBCL (2 GCB [Germinal-center B-cell-like], 3 non-GCB), 5 MCL, 3 MZL, 3 WM, and 2 FL. Patients enrolled were heavily pretreated with median prior lines of therapy of 4 (range 2–10) in NHL and 5 (range 2–11) in CLL. Prior treatments included: BTKi 100% (including covalent [cBTKi] and non-covalent [ncBTKi] inhibitors); BCL2 inhibitor 76%, with a large proportion of CLL patients exhibiting BTKi resistance mutations at baseline. Prior treatments in patients with NHL included: BTKi 72% (cBTKi and ncBTKi); bispecific antibody 1/18; bispecific antibody and CAR-T 1/18. There were two reported dose-limiting toxicities: one previously reported cognitive disturbance in a patient with CLL treated at 300 mg; and neutropenia in a patient with MZL treated at 300 mg. The most common any grade treatment-emergent adverse events (TEAEs) were fatigue (48.9%), neutropenia (42.6%) and hypertension (36.2%, see Table). The most common grade ≥3 TEAEs were neutropenia (38.3%), hypertension (14.9%) and anemia (12.8%). Contusion was reported in 27.7% of patients (all below grade 3), atrial fibrillation in 12.8% of patients (6.4% grade ≥3). Most common reasons for treatment discontinuation were progressive disease (PD, 25.5%) and AE (21.3%). Median follow-up for the study was 9.5 (range 0.1–24.3) months. NX-2127 exhibited dose-dependent pharmacokinetics (PK) with a mean half-life of 2–4 days across cohorts. Rapid, robust and sustained BTK degradation was observed in all patients, regardless of their absolute BTK starting level, tumor type, or dose level of NX-2127 (Figure). In addition, degradation of the cereblon neo-substrate Ikaros was observed. Among the efficacy evaluable patients with CLL, there were 9 PRs/PR with rebound lymphocytosis; additionally, 11 patients had SD at the time of data cut-off and 4 had PD. Two patients with WM were treated and efficacy evaluable (1 SD, 1 PD). Among the efficacy evaluable patients with NHL, there were 2 CRs and 1 PR; additionally, 3 patients had SD, and 5 had PD. Two CRs are ongoing with 9.2 and 11.8 months of duration.

Conclusion: This first-in-human study of NX-2127 is actively enrolling and dose-expansion cohorts in DLBCL and MCL have been initiated at the 300 mg daily dose. Findings include dose-dependent PK accompanied by degradation of BTK and Ikaros. Encouraging and persistent responses were observed in heavily pretreated patients with relapsed/refractory CLL and NHL with a manageable safety profile. These data support the
treatment concept of combining immunomodulatory activity and BTK degradation in a single molecule and support further development of NX-2127 in B cell malignancies.

![Figure. BTK expression in all patients receiving NX-2127](image)

**Table. Frequency of any grade TEAEs in ≥20% of patients or grade ≥3 TEAEs in >1 patient (N=47)**

<table>
<thead>
<tr>
<th>Adverse events, n (%)</th>
<th>TEAEs Any grade</th>
<th>TEAEs grade ≥3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fatigue</td>
<td>23 (48.9)</td>
<td>–</td>
</tr>
<tr>
<td>Neutropenia*</td>
<td>20 (42.6)</td>
<td>18 (38.3)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>17 (35.2)</td>
<td>7 (14.9)</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>14 (29.8)</td>
<td>–</td>
</tr>
<tr>
<td>Confusion*</td>
<td>13 (27.7)</td>
<td>–</td>
</tr>
<tr>
<td>Anemia</td>
<td>12 (25.5)</td>
<td>6 (12.8)</td>
</tr>
<tr>
<td>Thrombocytopenia*</td>
<td>12 (25.5)</td>
<td>3 (6.4)</td>
</tr>
<tr>
<td>Constipation</td>
<td>11 (23.4)</td>
<td>–</td>
</tr>
<tr>
<td>Dyspnea</td>
<td>10 (21.3)</td>
<td>1 (2.1)</td>
</tr>
<tr>
<td>Pruritus</td>
<td>10 (21.3)</td>
<td>1 (2.1)</td>
</tr>
<tr>
<td>Pneumonia</td>
<td>6 (12.8)</td>
<td>3 (6.4)</td>
</tr>
<tr>
<td>COVID</td>
<td>6 (12.8)</td>
<td>3 (6.4)</td>
</tr>
<tr>
<td>Atrial fibrillation</td>
<td>6 (12.8)</td>
<td>3 (6.4)</td>
</tr>
<tr>
<td>Leukocytosis</td>
<td>3 (6.4)</td>
<td>3 (6.4)</td>
</tr>
<tr>
<td>Lymphocyte count increased</td>
<td>2 (4.3)</td>
<td>2 (4.3)</td>
</tr>
<tr>
<td>Sepsis</td>
<td>2 (4.3)</td>
<td>2 (4.3)</td>
</tr>
</tbody>
</table>

*Aggregate of ‘neutropenia’ and ‘neutrophil count decreased’; *Confusion includes episodes of braving and other similar terms; *Aggregate of ‘thrombocytopenia’ and ‘platelet count decreased’.
Disclosures: Danilov: MEI: Consultancy, Research Funding; Lilly Oncology: Consultancy, Research Funding; Cyclacel: Research Funding; Nurix: Consultancy, Research Funding; Bayer: Research Funding; Abbvie: Consultancy, Research Funding; Beigene: Consultancy, Research Funding; Janssen: Consultancy; Astra Zeneca: Consultancy, Research Funding; Bristol Myers Squibb: Consultancy, Research Funding; Genentech: Consultancy; GenMab: Consultancy, Research Funding; Merck: Consultancy. Patel: Adaptive Biotechnologies, AstraZeneca, Bristol Myers Squibb, CRISPR Therapeutics, Curis, Inc, Epizyme, Fate Therapeutics, Genentech, Inc. / F. Hoffmann-La Roche Ltd, Kite, Loxo Oncology, MEI Pharma, Merck, Nurix, Pharmacyscics/Janssen, Sunesis Pharmaceuti: Research Funding; Abbvie, ADC Therapeutics, AstraZeneca, BeiGene, Bristol Myers Squibb, Caribou Biosciences, Epizyme, Genentech, Inc. / F. Hoffmann-La Roche Ltd, Kite, Loxo Oncology, MEI Pharma, Merck, Morphosys, Nurix, Pharmacyscics/Janssen, Sana Biotechnology, TG Therape: Consultancy, AstraZeneca, Bristol Myers Squibb, Kite, TG Therapeutics: Speakers Bureau. Wierda: Janssens Biotech: Research Funding; National Comprehensive Cancer Network: Other: Nonrelevant Financial Relationship/Chair, CLL. Supported by the NIH/NCI under award number P30 CA016672 and used MDACC Cancer Center Support Grant (CCSG) shared resources; Accutara Biotechnology: Research Funding; Juno Therapeutics: Research Funding; Pharmacyclics LLC: Research Funding; NIH P30 CA016672/MDACC Cancer Center Support Grant: Research Funding; Numab Therapeutics: Research Funding; Nurix Therapeutics: Research Funding; Loxo Oncology, Inc./Lilly: Research Funding; AstraZeneca/Acerta Pharma: Consultancy, Research Funding; Bristol Myers Squibb (Juno & Celgene): Consultancy, Research Funding; Gilead Sciences: Research Funding; GlaxoSmithKline: Research Funding; AbbVie: Consultancy, Research Funding; Genentech: Research Funding; Janssens Biotech Inc: Research Funding; GSK/Novartis: Research Funding; Cyclacel: Consultancy, Research Funding; Oncternal Therapeutics, Inc.: Research Funding; Sunesis: Research Funding; Miragen: Research Funding; KITE Pharma: Research Funding. Patel: Olema Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees; ION Pharmaceuticals: Other: Leadership; Janssen Oncology: Honoraria. Flinn: Servier Pharma: Consultancy; Secura Bio: Consultancy; Novartis: Consultancy; Myeloid Therapeutics: Consultancy; Kite: Consultancy; Innocare Pharma: Consultancy; Hutchinson MediPharma: Consultancy; Genmab: Consultancy; Genentech: Consultancy; Century Therapeutics: Consultancy; BeiGene: Consultancy; AbbVie: Consultancy; TG Therapeutics: Consultancy; Vincerx Pharma: Consultancy. Ai: Biomerieux: Honoraria; Kyowa Kirin: Honoraria; Secura Bio: Membership on an entity's Board of Directors or advisory committees. Thompson: Beigene: Consultancy, Research Funding; Abbvie: Consultancy, Research Funding; Loxo Oncology: Consultant; Lilly: Consultant; Janssen: Consultant; Dava Oncology: Honoraria; Other: Travel ; Curio Science: Honoraria; Massachusetts Medical Society: Honoraria; VJHemOnc: Honoraria; Genentech: Research Funding; Intellisphere LLC: Honoraria; Brazilian Association of Hematology, Hemotherapy and Cellular Therapy (ABHH): Honoraria; MJH Life Sciences: Honoraria, AstraZeneca: Consultancy, Research Funding; Genmab: Research Funding; Nurix Therapeutics: Other: travel support, Research Funding; Philips Group
**Oncology Communications**: Honoraria. **Wang**: Genentech: Consultancy, Research Funding; MD

**Education**: Honoraria; MJH Life Sciences: Honoraria; WebMD: Honoraria; Scripps: Honoraria; Studio ER

**Congressi**: Honoraria; Nurix: Honoraria; OncLive: Honoraria; Loxo Oncology: Consultancy, Research Funding; Moffit Cancer Center: Honoraria; Anticancer Association: Honoraria; Molecular Templates: Research Funding; IDEology Health: Honoraria; Vincerx: Research Funding; i3Health: Honoraria; Medscape: Honoraria; Eastern Virginia Medical School: Honoraria; Dava Oncology: Honoraria, Other: Travel; Celgene: Other: Travel, Research Funding; BGICS: Honoraria; Meeting Minds Experts: Honoraria; Genmab: Honoraria, Research Funding; Clinical Care Options: Honoraria; Epizyme: Consultancy, Honoraria; AstraZeneca: Consultancy, Honoraria, Other: Travel, Research Funding; CAHON: Honoraria; Bantam Pharmaceutical: Honoraria; VelosBio: Consultancy, Research Funding; Pharmacyclics: Consultancy, Honoraria, Research Funding; Pepromene Bio: Consultancy; Parexel: Consultancy; Oncternal: Consultancy, Research Funding; Milken Institute: Consultancy; Mitenyi Biomedicine: Consultancy; Merck: Consultancy, Honoraria; NIH: Honoraria; Be Biopharma: Consultancy; BeiGene: Consultancy, Honoraria, Research Funding; Oncology Specialty Group: Honoraria; Physicians Education Resources (PER): Honoraria, Other: Travel; Practice Point Communications (PPC): Honoraria; DTRM Biopharma (Cayman) Limited: Consultancy; Deciphera: Consultancy; Bristol Myers Squibb: Consultancy, Honoraria; BioInvent: Consultancy, Honoraria, Research Funding; Eli Lilly and Company: Consultancy, Research Funding; Leukemia & Lymphoma Society: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees; Kite, a Gilead Company: Consultancy, Honoraria, Other: Travel, Research Funding; Janssen: Consultancy, Honoraria, Research Funding; InnoCare: Consultancy, Research Funding; Genentech: Consultancy, Research Funding; Juno Therapeutics: Research Funding; OMI: Honoraria; Pharmacyclics: Honoraria; Physicians Education Resources: Honoraria; Practice Point Communications: Honoraria; CSTone: Consultancy; Amphista Therapeutics Limited: Consultancy; ADC Therapeutics America: Consultancy; Acerta Pharma: Consultancy, Honoraria, Research Funding; AbbVie: Consultancy, Honoraria; Hebei Cancer Prevention Federation: Honoraria; Imedex: Honoraria; TS Oncology: Honoraria; Mumbai Hematology Group: Honoraria. **Sun**: Genmab: Research Funding. **Stephens**: AbbVie: Consultancy; AstraZeneca: Consultancy, Research Funding; BeiGene: Consultancy, Bristol-Myers Squibb: Consultancy; Celgene: Consultancy; Genentech: Consultancy; Janssen: Consultancy; Lilly: Consultancy; Novartis: Research Funding. **Thirman**: AbbVie: Honoraria; Nurix: Research Funding; AbbVie: Research Funding; Merck: Research Funding; Syndax: Research Funding. **Gessner**: Nurix Therapeutics, Inc.: Current Employment, Current equity holder in publicly-traded company. **Wolff**: Nurix Therapeutics, Inc.: Current Employment, Current equity holder in publicly-traded company. **Schwab**: Nurix Therapeutics, Inc.: Current Employment, Current equity holder in publicly-traded company.
Employment, Current equity holder in publicly-traded company. **Tan:** Nurix Therapeutics, Inc.: Current Employment, Current equity holder in publicly-traded company. **Chan:** Nurix Therapeutics, Inc.: Current Employment, Current equity holder in publicly-traded company. **Meredith:** Nurix Therapeutics, Inc.: Current Employment, Current equity holder in publicly-traded company. **Wiestner:** Genmab: Research Funding; Acerta: Research Funding; Pharmacyclics: Research Funding; Merck: Research Funding; Nurix: Research Funding; Secura Bio: Research Funding. **OffLabel Disclosure:** NX-2127 is an oral, first-in-class, dual-function small molecule degrader that combines BTK degradation with the immunomodulatory activity of an Ikaros and Aiolos degrader.
INTRODUCTION

We aim to identify factors that impact outcomes of venetoclax for patients with CLL treated in routine practice at a tertiary center. We report on the use of venetoclax in the most frequently encountered disease scenarios: first-line, relapsed/Bruton tyrosine kinase inhibitor (BTKi)-naïve, and relapsed/BTKi-exposed.

METHODS

We identified patients who received venetoclax therapy for CLL (between 4/2012–4/2023) from the Mayo Clinic CLL Database. Undetectable measurable residual disease (uMRD) was defined as <1 CLL cell per 10,000 leukocytes using 8-color flow cytometry on peripheral blood (PB) or bone marrow (BM). Overall survival (OS) was defined as the time from venetoclax start until date of death or last known to be alive. Treatment-free survival (TFS) after venetoclax was defined as the time from venetoclax start until the earliest of date of next...
treatment, or death. Kaplan–Meier was used to display OS and TFS. Multivariable Cox proportional hazards regression models were used to estimate associations of factors with time-to-event outcomes.

RESULTS

A total of 155 patients received venetoclax: firstline therapy (in combination with obinutuzumab, n=55) and relapsed CLL (n=100; 17 had relapsed/BTKi-naïve CLL, and 83 had previously received BTKi [55 with progression after BTKi], relapsed/BTKi-exposed). The median follow-up for the cohorts of first-line therapy, relapsed/BTKi-naïve, and relapsed/BTKi-exposed was 12.9 months, 37.0 months, and 27.6 months, respectively. Baseline characteristics at the time of venetoclax initiation for all patients are shown in Table 1. The median TFS for the overall cohort was 39.0 months. The median OS was 54.6 months.

Among patients treated with venetoclax as first-line therapy (n=55), the 2-year TFS (Figure 1) and 2-year OS rates were both 91%. MRD testing was performed in 28 patients and was uMRD in 23 (82%) patients (only PB assessed, n=7; only BM assessed, n=2; PB and BM assessed, n=14). Detectable MRD was identified in 3 patients, and 2 patients had discordant results (PB uMRD and BM detectable disease).

Among patients treated with venetoclax in the relapsed/BTKi-naïve setting (n=17), the 2-year TFS rate was 73% (Figure 1) and the 2-year OS rate was 100%. MRD testing was performed in 7 patients and was uMRD in all 7 (100%) (only PB assessed, n=3; only BM assessed, n=2; PB and BM assessed, n=2). The median time to first uMRD result was 14.1 months.

Among relapsed/BTKi-exposed venetoclax-treated patients (n=83), the median TFS was 26.9 months (Figure 1), and the median OS was 39.4 months. In this subgroup, the median TFS for patients with (n=55) and without (n=28) prior disease progression on prior BTKi were 22.3 and 42.3 months, respectively. Median TFS with venetoclax monotherapy (n=30) was 24.0 months, venetoclax in combination with rituximab (n=37) was 26.9 months, and venetoclax in combination with obinutuzumab (n=16) was 39.0 months. BTKi-exposed patients that were chemotherapy-naïve (n=27) and chemotherapy-exposed (n=56) had median TFS of 29.1 and 24.0 months, respectively. MRD testing was performed in 28 patients and was uMRD in 16 (57%) patients (only PB assessed, n=9; only BM assessed, n=2; PB and BM assessed, n=5). Detectable MRD was identified in 11 patients, and 1 had discordant results (PB uMRD and BM detectable disease). The median time to first uMRD result was 11.5 months.

TP53 disruption, unmutated IGHV genes, older age, complex karyotype (CK; defined as more than 3 chromosomal aberrations on CpG stimulated karyotype), and disease progression on prior BTKi were associated with shorter TFS in the overall cohort on univariate analysis. TP53 disruption, older age, CK, and disease progression on prior BTKi were associated with shorter OS in the overall cohort on univariate analysis. Multivariable analysis was performed by including only those patients where all variables significant in univariable analysis were available (OS model n=65, TFS model n=53). In these models, only CK was significantly associated with shorter TFS (HR 8.5; 95%CI 2.5-29.1; P<0.001) and shorter OS (HR 4.1; 95%CI 1.2-14; P=0.03).
CONCLUSIONS

Patients with BTKi-exposed CLL, particularly those with prior disease progression on BTKi, had worse outcomes. Our study identified CK as one of the most important baseline predictors of adverse TFS and OS in the overall cohort of patients, supporting karyotype assessment for prognostication prior to venetoclax treatment.

Table 1: Baseline characteristics at the time of venetoclax start

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Number (%) or Median [range]</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>All patients</td>
</tr>
<tr>
<td><strong>N</strong></td>
<td>166</td>
</tr>
<tr>
<td>Age, years</td>
<td>66 (41-83)</td>
</tr>
<tr>
<td>Males</td>
<td>106 (64)</td>
</tr>
<tr>
<td>Prior lines of therapy</td>
<td>1 (0-11)</td>
</tr>
<tr>
<td>Combination with anti-CD20ab</td>
<td></td>
</tr>
<tr>
<td>Rituximab</td>
<td>45 (29)</td>
</tr>
<tr>
<td>Obinutuzumab</td>
<td>80 (52)</td>
</tr>
<tr>
<td>Monotherapy</td>
<td>30 (19)</td>
</tr>
<tr>
<td>Rai stage, n=148</td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>25 (15)</td>
</tr>
<tr>
<td>II</td>
<td>62 (42)</td>
</tr>
<tr>
<td>III/IV</td>
<td>60 (45)</td>
</tr>
<tr>
<td>Absolute Lymphocyte Count x 10^9/L</td>
<td>22.4 (6-93)</td>
</tr>
<tr>
<td>IGHV mutation status, n=129</td>
<td></td>
</tr>
<tr>
<td>Unmutated</td>
<td>93 (72)</td>
</tr>
<tr>
<td>FISH, n=134</td>
<td></td>
</tr>
<tr>
<td>None detected</td>
<td>20 (15)</td>
</tr>
<tr>
<td>Other</td>
<td>5 (4)</td>
</tr>
<tr>
<td>13q</td>
<td>24 (19)</td>
</tr>
<tr>
<td>Trisomy 12</td>
<td>33 (24)</td>
</tr>
<tr>
<td>11q</td>
<td>28 (21)</td>
</tr>
<tr>
<td>17p</td>
<td>24 (18)</td>
</tr>
<tr>
<td>Complex karyotype, n=68</td>
<td></td>
</tr>
<tr>
<td>Complex (3 or 4 abnormalities)</td>
<td>27 (39)</td>
</tr>
<tr>
<td>TP53 Deletion (either del17p or del1p53 mutation), n=136</td>
<td>32 (24)</td>
</tr>
</tbody>
</table>

*Not available for all patients

Disclosures: Wang: Eli Lilly: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Incyte: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Morphosys: Research Funding; Kite: Honoraria, Membership on an entity’s Board of Directors or advisory committees; TG Therapeutics: Membership on an entity’s Board of Directors or advisory committees; Genmab: Research Funding; Janssen: Membership on an entity’s Board of Directors or advisory committees; LOXO Oncology: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Innocare: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Genentech: Research Funding; Novartis: Research Funding; BeiGene: Membership on an entity’s Board of Directors or advisory committees; AstraZeneca: Membership on an entity’s Board of Directors or advisory committees; AbbVie: Consultancy. Kenderian: Mettaforge: Patents & Royalties; LEAHLabs: Consultancy, Current equity holder in private company, Research Funding; Lentigen: Research Funding; Novartis: Consultancy, Honoraria, Patents & Royalties, Research Funding, Speakers Bureau; Sendero: Patents & Royalties; MustangBio: Patents & Royalties; Humanigen: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Patents & Royalties, Research Funding, Speakers
Bureau; **Juno/BMS**: Other: Membership on an entity's board of directors or advisory committees, Research Funding; **CapstanBio**: Consultancy, Other: Scientific advisory board; **Luminary therapeutics**: Other: scientific advisory board ; **Morphosys**: Research Funding; **Tolero/Sumtomo**: Research Funding; **Torque**: Consultancy; **Kite/Gilead**: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding. **Ding**: **DTRM**: Research Funding; **BeiGene**: Consultancy, Honoraria, Research Funding; **Merck**: Consultancy, Honoraria, Research Funding; **Alexion**: Consultancy, Honoraria; **MEI pharma**: Consultancy, Honoraria; **AstraZeneca**: Research Funding; **Octapharma**: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; **AbbVie**: Research Funding. **Muchtar**: **Protego**: Consultancy. **Koehler**: **AbbVie**: Consultancy, Other: Advisory Board; **Janssen**: Other: Advisory Board; **Astra Zeneca**: Other: Advisory Board. **Tsang**: **Poseida Therapeutics**: Current holder of stock options in a privately-held company; **Novartis**: Consultancy. **Kay**: **Abbvie**: Membership on an entity's Board of Directors or advisory committees, Research Funding; **Acerta Pharma**: Research Funding; **Bristol Meyer Squib / Celgene**: Membership on an entity's Board of Directors or advisory committees, Research Funding; **Genentech**: Research Funding; **Pharmacyclics**: Membership on an entity's Board of Directors or advisory committees, Research Funding; **Sunesis**: Research Funding; **Vincerx**: Research Funding; **Agios Pharm**: Membership on an entity's Board of Directors or advisory committees; **Astra Zeneca**: Membership on an entity's Board of Directors or advisory committees; **Dren Bio**: Membership on an entity's Board of Directors or advisory committees; **Janssen**: Membership on an entity's Board of Directors or advisory committees; **Behring**: Membership on an entity's Board of Directors or advisory committees; **Beigene**: Membership on an entity's Board of Directors or advisory committees; **boehringer ingelheim**: Membership on an entity's Board of Directors or advisory committees; **Dava Oncology**: Membership on an entity's Board of Directors or advisory committees; **Juno Therapeutics**: Membership on an entity's Board of Directors or advisory committees. **Parikh**: **AbbVie Inc**: Membership on an entity's Board of Directors or advisory committees, Research Funding; **AstraZeneca**: Membership on an entity's Board of Directors or advisory committees; **Agios Pharmaceuticals**: Membership on an entity's Board of Directors or advisory committees; **Accerta Pharmaceuticals**: Research Funding; **Bristol Myers Squibb-Celgene**: Membership on an entity's Board of Directors or advisory committees, Research Funding; **Sunesis**: Research Funding; **Genentech**: Research Funding; **Dren Bio**: Membership on an entity's Board of Directors or advisory committees; **Juno Therapeutics**: Membership on an entity's Board of Directors or advisory committees; **Pharmacyclics**: Membership on an entity's Board of Directors or advisory committees, Research Funding; **Vincerx**: Research Funding; **Beigene**: Membership on an entity's Board of Directors or advisory committees; **CSL Behring**: Membership on an entity's Board of Directors or advisory committees; **Boehringer Ingelheim Pharmaceuticals Incc**: Membership on an entity's Board of Directors or advisory committees; **Dava Oncology**: Membership on an entity's Board of Directors or advisory committees; **Janssen**: Membership on an entity's Board of Directors or advisory committees.
108 Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter’s Transformation: An International Multicenter Retrospective Study

Program: Oral and Poster Abstracts
Type: Oral
Session: 705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Cellular Therapy for B Cell Lymphomas: Prospective Clinical Trials and Real World Data
Hematology Disease Topics & Pathways:
Lymphoid Leukemias, Biological therapies, CLL, Lymphomas, non-Hodgkin lymphoma, B Cell lymphoma, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Diseases, aggressive lymphoma, Therapies, Lymphoid Malignancies

Saturday, December 9, 2023: 10:45 AM

Adam S Kittai, MD, David A. Bond, MD, BS, Ying Huang, MS, MA, Seema A Bhat, MD, Emily Blyth, MD, PhD, John C. Byrd, MD, Julio C Chavez, MD, Matthew S. Davids, MD, MMSc, Jamie P Dela Cruz, Mark R Dowling, MBBS, PhD, Caitlyn Duffy, Carrie I Ho, MD, Caron A Jacobson, MD, MMSc, Samantha M. Jaglowski, MD, MPH, Nitin Jain, MD, Kevin H Lin, MD, Christine McCarthy, BS, Erin M Parry, MD, PhD, Manoj Rai, MD, Kerry A Rogers, MD, Aditi Saha, MBBS, Levanto Schachter, DO, MS, Hamish Scott, MD, Jayastu Senapati, MD, MBBS, DM, Mazyar Shadman, MD, MPH, Tanya Siddiqi, MD, Deborah M. Stephens, DO, Vinay Vanguru, MBBS, FRACP, FRCPA, William G. Wierda, MD, PhD, Omer Zulfa, MD, Jennifer A. Woyach, MD, and Philip A. Thompson, MBBS

1Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH
2The James Cancer Center, The Ohio State University Wexner Medical Center, Columbus, OH
3Division of Hematology, The Ohio State University, Columbus, OH
4Westmead Hospital, Sydney, Australia
5Department of Internal Medicine, University of Cincinnati, Cincinnati, OH
6Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL
7Department of Medical Oncology, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA
8Peter MacCallum Cancer Centre, Department of Clinical Haematology, Royal Melbourne Hospital, Melbourne, Australia
9Division of Medical Oncology, University of Washington, Seattle, WA
10Dana-Farber Cancer Institute, Boston, MA
11Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
12Department of Medicine, Brigham and Women's Hospital, Boston, MA
13City of Hope National Medical Center, Duarte, CA
14Center for Hematologic Malignancies, Knight Cancer Institute, Oregon Health and Sciences University, Portland,
Background: 
Aggressive lymphoma, most commonly large B-cell lymphoma (LBCL), arising in the setting of chronic lymphocytic leukemia (CLL) is known as Richter’s transformation (RT), and is associated with poor outcomes. CD19 CART has revolutionized the treatment (tx) of LBCL, with durable responses for patients (pts) with relapsed/refractory disease. Pts with RT have been excluded from most major CD19 CART trials. Therefore, there is limited data describing outcomes of pts with RT receiving CD19 CART.

Methods: 
We conducted an international multicenter retrospective study of pts with RT who received CD19 CART approved for hematologic malignancies at 9 academic centers. RT was defined as pts with LBCL with preceding or concurrently diagnosed CLL. We collected pt, disease, and tx characteristics. Progression-free survival (PFS) and overall survival (OS) were measured from date of CD19 CART infusion and estimated using the Kaplan-Meier method. Cox regression model was used to associate prognostic factors with PFS and OS. Response was assessed by Lugano criteria.

Results: 
62 pts were included. Median age at CD19 CART infusion was 65 (range: 27-80). Median prior lines of therapy for CLL or RT were both 2 (CLL range: 0-10, RT range: 0-7). 52 (84%) pts previously received a Bruton tyrosine kinase inhibitor (BTKi) or BCL2 inhibitor (BCL2i) for CLL or RT. Median Ki-67 on pathology sample was 80% (range: 40-100), median SUV on brightest lymph node (LN) on PET-CT was 15.0 (range: 3-50.6), median size of largest LN was 3.8cm (range: 0-16), and median LDH prior to CD19 CART was 244 (range: 96-2878, ULN range: 190-271). Median time from apheresis to CD19 CART infusion was 33 days (range: 24-100), and 52 (84%) pts received bridging therapy. 40 (65%), 14 (23%), 7 (11%), and 1 (2%) pts received axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tisa-cel), lisocabtagene maraleucel (liso-cel), and brexucabtagene autoleucel (brexu-cel), respectively.

Overall response rate was 65%, with 29 (47%) and 11 (18%) pts attaining complete response (CR) and partial response (PR), respectively. After a median follow up of 24.1 months (mos) from CD19 CART infusion, the median PFS was 4.7 mos (95% CI: 2.3-6.9), and median OS was 8.5 mos (95% CI: 5.1-32.5) (Figure). Median duration of response was 14.5 mos (95% CI: 4.0-NR), with a median not reached (NR) (95% CI: 13.1-NR) for pts...
who achieved a CR, and a median of 2.3 mos (95% CI: 1.0-3.3) for pts who achieved a PR. Among 39 pts who died, 28 (72%) died due to progression of disease (PD), and 11 (28%) died for other reasons including 8 infections (4 COVID), 1 septic shock, 1 stroke, and 1 respiratory failure. The cumulative incidence of non-relapse mortality at 12 mos was 13% (95% CI: 6.2-23.4). 3 pts in a CR underwent allogeneic stem cell transplantation, 2 were alive at last known follow up (3.9 and 24.2 mos post-transplant), and 1 pt died from PD 21 mos post-transplant. 55 (89%) pts had CRS, with 9 (15%) grade ≥3 events. 43 (69%) pts had ICANS, with 23 (38%) grade ≥3 events.

On univariable analysis, increasing Ki-67 and LDH were found to be associated with worse PFS and OS, and attaining a CR with CD19 CART was found to be associated with improved PFS and OS. On multivariable analysis, increasing Ki-67 and LDH, and greater number of prior lines of therapy for RT were independent prognostic variables for worse PFS and OS, and attaining a CR was associated with improved OS. All other variables, including type of CD19 CART product received, were not correlated with PFS or OS (Table).

Conclusions:
We report findings from the largest cohort of pts with RT who received CD19 CART. Of note, 84% of pts were exposed to either BTKi or BCL2i for the tx of CLL or RT. RT remains a disease of unmet need, as the median OS was 8.5 mos in this study. However, there is some progress made as historically the median OS for patients with RT previously treated with BTKi is 4 mos (Kittai et al AJH 2023). Given higher number of prior therapies is associated with worse OS, earlier use of CD19 CART in the RT disease course may be warranted. Our data support the use of CD19 CART for pts with RT, with durable disease control in a subset of pts, however there is clear room to improve and develop better therapies. Given observed high response rate to CD19 CART, along with most pts experiencing early relapse, allogeneic stem cell transplantation at response should be
considered. Prospective clinical trials evaluating CD19 CART with novel agents for RT are currently ongoing.

Table. Univariable and Multivariable Cox Model for OS

<table>
<thead>
<tr>
<th>Univariable Models</th>
<th>Multivariable Model</th>
</tr>
</thead>
<tbody>
<tr>
<td>HR (95% CI)</td>
<td>p-value</td>
</tr>
<tr>
<td>Age at CD19 CART infusion, 5-years older</td>
<td>1.00 (0.86-1.16)</td>
</tr>
<tr>
<td># prior lines of therapy for CLL prior to RT</td>
<td>1.11 (0.92-1.32)</td>
</tr>
<tr>
<td># prior lines of therapy for RT prior to CART</td>
<td>3.31 (1.02-10.68)</td>
</tr>
<tr>
<td>Total prior lines of therapy</td>
<td>1.17 (1.02-1.35)</td>
</tr>
<tr>
<td>Presence of del17p or TP53 in preceding CLL</td>
<td>0.99 (0.49-2.04)</td>
</tr>
<tr>
<td>Ever received prior BTKi or Ven for CLL or RT, vs No</td>
<td>-</td>
</tr>
<tr>
<td>Received BTKi or BCL2i for CLL but not RT</td>
<td>2.66 (0.69-10.18)</td>
</tr>
<tr>
<td>Received BTKi or BCL2i for RT but not CLL</td>
<td>2.12 (0.69-6.48)</td>
</tr>
<tr>
<td>Received BTKi or BCL2i for both CLL and RT</td>
<td>1.19 (0.44-3.18)</td>
</tr>
<tr>
<td>Ki-67, 10% higher</td>
<td>1.44 (1.12-1.84)</td>
</tr>
<tr>
<td>LDH, 2-fold increase</td>
<td>1.95 (1.40-2.71)</td>
</tr>
<tr>
<td>SUV, 1-unit increase</td>
<td>1.01 (0.99-1.04)</td>
</tr>
<tr>
<td>Size of LN, 1-cm increase</td>
<td>1.01 (0.92-1.10)</td>
</tr>
<tr>
<td>Received BTKi concurrently with CART*</td>
<td>0.73 (0.39-1.37)</td>
</tr>
<tr>
<td>Days from apheresis to CD19 CART, 5 more days</td>
<td>1.05 (0.93-1.19)</td>
</tr>
<tr>
<td>Received bridging therapy</td>
<td>1.25 (0.49-3.21)</td>
</tr>
<tr>
<td>Achieving CR vs. not achieving CR**</td>
<td>0.19 (0.08-0.46)</td>
</tr>
<tr>
<td>Types of CD19 CART therapy, vs Brexu-cel or Liso-cel</td>
<td>-</td>
</tr>
<tr>
<td>Avi-cel</td>
<td>0.78 (0.30-2.06)</td>
</tr>
<tr>
<td>Tisa-cel</td>
<td>0.63 (0.21-1.89)</td>
</tr>
</tbody>
</table>

* Received BTKi as part of the most recent therapy prior to apheresis, or as part of the bridging tx or concurrently with CD19 CART.

** Entered model as a time dependent variable.
Disclosures: **Kittai**: Abbvie: Consultancy; AstraZeneca: Consultancy, Research Funding; Beigene: Consultancy, Research Funding, Speakers Bureau; Eli Lilly: Consultancy; Janssen: Consultancy; KITE: Consultancy; BMS: Consultancy. **Bond**: Novartis: Consultancy, Research Funding; Nurix Therapeutics: Consultancy, Research Funding; SeaGen: Consultancy; Incyte: Research Funding. **Bhat**: Aptitude Health: Honoraria; Abbvie: Consultancy; AstraZeneca: Consultancy, Research Funding. **Blyth**: MSD: Honoraria; Novartis: Honoraria; Bastion.

**Education**: Honoraria; IQVIA: Consultancy. **Byrd**: Orbimed: Consultancy, Research Funding; OSU Drug Devel.

**Inst.**: Consultancy; Kurome: Current equity holder in publicly-traded company, Membership on an entity’s Board of Directors or advisory committees; Newave: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Vincerx: Current equity holder in publicly-traded company, Membership on an entity’s Board of Directors or advisory committees; Eilean Therapeutics: Consultancy, Current equity holder in private company, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Orange Grove Bio: Membership on an entity’s Board of Directors or advisory committees; American Cancer: Membership on an entity’s Board of Directors or advisory committees; AstraZeneca: Other: TRAVEL, ACCOMMODATIONS, EXPENSES. **Chavez**: Cellectar: Membership on an entity’s Board of Directors or advisory committees; BMS: Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; Karyopharm: Membership on an entity’s Board of Directors or advisory committees; Kite/Gilead: Membership on an entity’s Board of Directors or advisory committees; Adaptive: Research Funding; ADC Therapeutics: Membership on an entity’s Board of Directors or advisory committees, Research Funding; AstraZeneca: Research Funding; Beigene: Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; Epizyme: Speakers Bureau; Genmab: Honoraria; Lilly: Honoraria; Merck: Research Funding; Morphosys: Speakers Bureau; Novartis: Membership on an entity’s Board of Directors or advisory committees. **Davids**: Merck: Consultancy; Surface Oncology: Research Funding; Takeda: Consultancy; Novartis: Research Funding; Beigene: Consultancy; BMS: Consultancy; Curio Science: Consultancy; Eli Lilly: Consultancy; Genentech: Consultancy, Research Funding; Janssen: Consultancy; Mingsight Pharmaceuticals: Consultancy; Research to Practice: Consultancy; Secura Bio: Consultancy; TG Therapeutics: Consultancy, Research Funding; Aptitude Health: Consultancy; Adaptive Biosciences: Consultancy; Ascentage Pharma: Consultancy, Research Funding; AstraZeneca: Consultancy, Research Funding; MEI Pharma: Research Funding; ONO Pharmaceuticals: Consultancy; AbbVie: Consultancy, Research Funding. **Dowling**: Abbvie: Patents & Royalties; Gilead: Honoraria; Novartis: Honoraria. **Jacobson**: Kite, a Gilead company: Consultancy, Honoraria, Research Funding; Novartis: Consultancy, Honoraria, Other: Travel support; Bristol Myers Squibb/Celgene: Consultancy; Abbvie: Consultancy, Honoraria; ADC Therapeutics: Consultancy; AstraZeneca: Consultancy, Abintus Bio: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Caribou Bio: Consultancy; Instil
Bio: Consultancy, Honoraria; ImmPACT Bio: Consultancy, Honoraria; Daiichi-Sankyo: Consultancy, Honoraria; Ipsen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Morphosys: Consultancy; Synthekine: Consultancy, Honoraria; Pfizer: Research Funding; Miltenyi

Biotec: Consultancy; Sana: Consultancy, Honoraria; BMS: Consultancy, Honoraria; Celgene: Consultancy, Honoraria, Other: Travel support; Lonza: Consultancy, Honoraria, Other: Travel support; Epizyme: Consultancy, Honoraria; Bluebird

Bio: Consultancy, Honoraria; Humanigen: Consultancy, Honoraria, Other: Travel support; Nkarta: Consultancy, Honoraria; Precision BioSciences: Consultancy, Honoraria, Other: Travel support; Clinical Care Options: Speakers Bureau; Axis: Speakers Bureau. Jaglowski: CRISPR: Consultancy; Takeda: Consultancy; Bristol-Myers Squibb: Consultancy, Research Funding; Novartis: Consultancy, Research Funding; Kite. a Gilead Company: Consultancy, Research Funding; Caribou: Research Funding. Jain: Incyte: Research Funding; Pfizer: Research Funding; Fate Therapeutics: Research Funding; Medisix: Research Funding; Novalgen: Research Funding; Loxo Oncology: Research Funding; Janssen: Consultancy, Honoraria, Other: Travel, Accommodations, Expenses; Mingsight: Research Funding; Takeda: Research Funding; AstraZeneca: Consultancy, Honoraria, Other: Travel, Accommodations, Expenses, Research Funding; BMS: Consultancy, Honoraria, Other: Travel, Accommodations, Expenses, Research Funding; AbbVie: Consultancy, Honoraria, Other: Travel, Accommodations, Expenses, Research Funding; Kite/Gilead: Consultancy, Honoraria, Other: Travel, Accommodations, Expenses, Research Funding; Cellectis: Consultancy, Honoraria, Other: Travel, Accommodations, Expenses, Research Funding; Pharmacyclics: Consultancy, Honoraria, Other: Travel, Accommodations, Expenses, Research Funding; Dialectic Therapeutics: Research Funding; Adaptive Biotechnologies: Consultancy, Honoraria, Other: Travel, Accommodations, Expenses, Research Funding; Precision Biosciences: Consultancy, Honoraria, Other: Travel, Accommodations, Expenses, Research Funding; Beigene: Consultancy, Honoraria, Other: Travel, Accommodations, Expenses; MEI Pharma: Consultancy, Honoraria, Other: TRAVEL, ACCOMMODATIONS, EXPENSES; Aprea Therapeutics: Research Funding; ADC Therapeutics: Research Funding; Servier: Research Funding; CareDX: Consultancy, Honoraria, Other: Travel, Accommodations,

Expenses; Genentech: Consultancy, Honoraria, Other: Travel, Accommodations, Expenses, Research Funding; Ipsen: Consultancy, Honoraria, Other: TRAVEL, ACCOMMODATIONS, EXPENSES; TG Therapeutics: Consultancy, Honoraria, Other: Travel, Accommodations, Expenses; TransThera Sciences: Research Funding; Newave: Research Funding. Rogers: AstraZeneca: Consultancy; Beigene: Consultancy, Genentech: Consultancy, Research Funding; AbbVie: Consultancy, Research Funding; Janssen: Consultancy; Loxo@Lilly: Consultancy; Novartis: Research Funding; Pharmacyclics: Consultancy. Senapati: Kite Pharma: Other: Advisory
Board. **Shadman**: Vincerx: Research Funding; **Bristol Myers Squibb**: Consultancy, Research Funding; **AbbVie**: Consultancy, Research Funding; **Genentech**: Consultancy, Research Funding; **AstraZeneca**: Consultancy, Research Funding; **MorphoSys/Incyte**: Consultancy, Research Funding; **Pharmacyclics**: Consultancy, Research Funding; **Genmab**: Consultancy, Research Funding; **Eli Lilly**: Consultancy; **Kite, a Gilead Company**: Consultancy; **BeiGene**: Consultancy, Research Funding; **Mustang Bio**: Consultancy, Research Funding; **ADC therapeutics**: Consultancy; **Fate Therapeutics**: Consultancy; **TG Therapeutics**: Research Funding; **Regeneron**: Consultancy; MEI Pharma: Consultancy; **Janssen**: Consultancy. **Siddiqi**: AstraZeneca: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; **BMS**: Membership on an entity’s Board of Directors or advisory committees, Research Funding, Speakers Bureau; **BeiGene**: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; **Abbvie**: Membership on an entity's Board of Directors or advisory committees; **Gilead**: Membership on an entity's Board of Directors or advisory committees. **Stephens**: AbbVie: Consultancy; AstraZeneca: Consultancy, Research Funding; BeiGene: Consultancy; Bristol-Myers Squibb: Consultancy; Celgene: Consultancy; Genentech: Consultancy; Janssen: Consultancy; Lilly: Consultancy; Novartis: Research Funding. **Wierda**: Accutax Biotechnology: Research Funding; National Comprehensive Cancer Network: Other: Nonrelevant Financial Relationship/Chair, CLL). Supported by the NIH/NCI under award number P30 CA016672 and used MDACC Cancer Center Support Grant (CCSG) shared resources; **NIH P30 CA016672/MDACC Cancer Center Support Grant**: Research Funding; Cyclacel: Consultancy, Research Funding; Janssens Biotech Inc: Research Funding; Juno Therapeutics: Research Funding; Loxo Oncology, Inc./Lilly: Research Funding; Nurix Therapeutics: Research Funding; Numab Therapeutics: Research Funding; GlaxoSmithKline: Research Funding; Genentech: Research Funding; Janssens Biotech: Research Funding; Oncternal Therapeutics, Inc.: Research Funding; Miragen: Research Funding; Sunesis: Research Funding; KITE Pharma: Research Funding; Bristol Myers Squibb (Juno & Celgene): Consultancy, Research Funding; Gilead Sciences: Research Funding; Pharmacyclics LLC: Research Funding; AstraZeneca/Acerta Pharma: Consultancy, Research Funding; AbbVie: Consultancy, Research Funding; GSK/Novartis: Research Funding. **Woyach**: Newave: Consultancy; Loxo: Consultancy; Beigene: Consultancy, Research Funding; AstraZeneca: Consultancy; Abbvie: Consultancy; Schrodinger: Research Funding; Morphosys: Research Funding; Karyopharm: Research Funding; Janssen: Consultancy, Research Funding; Pharmacyclics: Consultancy, Research Funding. **Thompson**: merck: Consultancy, Speakers Bureau; Lilly: Consultancy; Janssen: Consultancy, Speakers Bureau; genentech: Consultancy; beigene: Consultancy; astraZeneca: Consultancy, Speakers Bureau; adaptive biotechnologies: Consultancy, Research Funding, Speakers Bureau; abbbv: Consultancy; pharmacyclics: Consultancy.
1737 Pirtobrutinib in Richter Transformation: Updated Efficacy and Safety Results with 18-Month Median Survival Follow-up from the Phase 1/2 BRUIN Study

Program: Oral and Poster Abstracts
Session: 626. Aggressive Lymphomas: Prospective Therapeutic Trials: Poster I
Hematology Disease Topics & Pathways:
Research, clinical trials, Lymphoid Leukemias, CLL, Lymphomas, Non-Biological therapies, Clinical Research, B Cell lymphoma, drug development, Diseases, Therapies, Lymphoid Malignancies
Saturday, December 9, 2023, 5:30 PM-7:30 PM

William G. Wierda, MD, PhD; Nirav N. Shah, MD; Chan Yoon Cheah, MD; David Lewis, MBChB, PhD; Marc Hoffmann, MD, Catherine C. Coombs, MD; Nicole Lamanna, MD; Shuo Ma, MD, PhD; Deepa Jagadeesh, MD; Talha Munir, MBBS, MRCP, FRCPath, PhD; Yucai Wang, MD, PhD; Toby A. Eyre; Joanna M. Rhodes, MD; Matthew McKinney, MD; Ewa Lech-Maranda, MD, PhD; Constantine S. Tam, MD, MBBS; Wojciech Jurczak, MD, PhD; Koji Izutsu, MD, PhD; Alvaro J. Alencar, MD; Manish Patel, MD; John F. Seymour, MBBS, PhD, FRACP; Jennifer A. Woyach, MD; Lindsey E. Roeker, MD; Philip A. Thompson, MBBS; Paolo Abada, MD; Caleb Ho, M.D.; Narasimha Marella, Ph.D.; Chunxiao Wang, Ph.D.; Amy S. Ruppert, Ph.D.; Binoj Chandrasekharan Nair, Ph.D.; Hui Liu, Ph.D.; Donald E. Tsai, MD, PhD and Paolo Ghia, MD, PhD

1Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX
2Medical College of Wisconsin, Milwaukee, WI
3Linnear Clinical Research and Sir Charles Gairdner Hospital and University of Western Australia, Perth, Australia
4University Hospitals Plymouth NHS Trust, Plymouth, United Kingdom
5The University of Kansas Medical Center, Kansas City, KS
6University of California, Irvine, Irvine, CA
7Herbert Irving Comprehensive Cancer Center, Columbia University, New York
8Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL
9Cleveland Clinic, Cleveland, OH
10Department of Haematology, St. James's University Hospital, Leeds, United Kingdom
11Division of Hematology, Mayo Clinic, Rochester, MN
12Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Center, Oxford, United Kingdom
13Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
14Duke Cancer Institute, Durham, NC
15Institute of Hematology and Transfusion Medicine, Warsaw, Poland
16The Alfred Hospital and Monash University, Melbourne, VIC, Australia
17Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland
Background: Richter transformation (RT) occurs in up to 10% of patients with chronic lymphocytic leukemia (CLL), typically presents as an aggressive diffuse large B-cell lymphoma (DLBCL) and is associated with poor survival. RT has no approved standard therapy, and clinical trial enrollment is the preferred first line of therapy. Pirtobrutinib, a highly selective, non-covalent (reversible) BTKi, that inhibits both wildtype and C481-mutant BTK with equal low nM potency, has favorable oral pharmacology that enables continuous BTK inhibition throughout the dosing interval. Pirtobrutinib demonstrated durable overall response rates (ORR) and was well tolerated in patients (pts) with poor-prognosis B-cell malignancies regardless of prior therapy. Here we provide updated safety and efficacy of pirtobrutinib in RT pts from the phase 1/2 BRUIN trial (NCT03740529).

Methods: Pts with previously treated, histologically confirmed RT were eligible in the global, multicenter, phase 1/2 BRUIN study. Pts with untreated RT became eligible after Amendment 10. All but one patient received the recommended phase 2 dose of 200 mg daily. Key endpoints included investigator-assessed ORR, DoR per Lugano 2014 criteria, OS, and safety. A data cut of 05 May 2023 was utilized. To assess clonal relationship, IGH rearrangement studies were done on tissue biopsies with RT involvement, and baseline blood or bone marrow (BM) samples with CLL involvement.

Results: Among all pts with RT (N=82) the median age was 67 (range, 26-95) and the median total number of lines of prior systemic therapy was 4 (range, 0-13). Pts with prior treatment had a median of 2 CLL-directed therapies and 2 RT-directed therapies. Eight pts did not have a previous line of RT-directed therapy, and 1 patient received neither RT- nor CLL-directed therapy. Common prior RT- and CLL-directed therapies (RT, CLL) included: chemotherapy (76%, 52%), cBTKi (34%, 62%), anti-CD20 antibody (78%, 66%), BCL2i (38%, 49%), stem cell transplant (SCT; 6%, 7%), and CAR-T (11%, 4%). Of 29 pts with bone marrow screening, 41.4% had CLL alone present in BM, 13.8% had DLBCL present and 24.1% had both CLL and DLBCL present. For 39 pts with available PET data, the median SUVmax was 19.1 (range, 2.6-41.2).

For all 82 pts, the ORR was 50.0% (95% CI, 38.7-61.3) including complete (13.4%, n=11) and partial (36.6%, n=30) responses. For 61 pts who received prior cBTKi therapy, the ORR was 45.9% (95% CI 33.1-59.2).
28 pts with an RT-directed cBTKi and 51 pts with prior CLL-directed cBTKi, the ORR was 42.9% (95% CI, 24.5-62.8) and 43.1% (95% CI, 29.3-57.8), respectively. In 50 pts who discontinued prior cBTKi due to disease progression, the ORR was 42.0% (95% CI, 28.2-56.8). At median follow-up time of 9.7 months, the median DoR for all 82 RT pts was 7.4 months (95% CI, 3.1-19.1) and the estimated rate at 12 months was 45.9% (95% CI, 28.3-61.8). The median time on treatment for the 41 pts who responded to treatment was 8.3 months. Eight pts stopped pirtobrutinib to pursue curative-intent allogeneic SCT and DoR was censored at the last preceding disease assessment. At a median survival follow-up of 18.3 months, the median OS for the entire RT cohort was 12.5 months (95% CI, 6.9-20.5). At 18 months, the OS rate was 44.3% (95% CI, 32.5-55.4).

Frequent treatment-emergent adverse events (TEAE) in the RT cohort (n=82) were neutropenia/decreased neutrophil count (29.3%, n=24), fatigue (24.4%, n=20) and diarrhea, dyspnea, thrombocytopenia, and pyrexia (18.3% each, n=15). Common grade ≥3 TEAEs were neutropenia/decreased neutrophil count (23.2%, n=19), thrombocytopenia (11.0%, n=9), plus anemia and sepsis (9.8% each, n=8). Any grade hypertension (3.7%, n=3) or atrial fibrillation (1.2%, n=1) were infrequent. Three pts (3.7%) had treatment-related AEs leading to dose reductions, but no pt had a treatment-related AE leading to pirtobrutinib discontinuation. Analyses of clonality will be presented.

**Conclusions:** Continued follow-up from BRUIN demonstrates encouraging response and OS in pts with RT. Pirtobrutinib remains well-tolerated with low rates of discontinuation and manageable safety profile. While RT remains a challenging diagnosis, pirtobrutinib represents a potential treatment option that warrants further investigation.
A. Efficacy in pre-treated RT patients with prior therapy indicated.

B. Overall survival in pre-treated patients with RT.

Median (months) 95% CI
12.5 6.9-20.5
Disclosures: Wierda: Numab Therapeutics: Research Funding; Loxo Oncology, Inc./Lilly: Research Funding; Janssens Biotech Inc: Research Funding; NIH P30 CA016672/MDACC Cancer Center Support Grant: Research Funding; GlaxoSmithKline: Research Funding; AbbVie: Consultancy, Research Funding; Cyclacel: Consultancy, Research Funding; Nurix Therapeutics: Research Funding; Juno Therapeutics: Research Funding; National Comprehensive Cancer Network: Other: Nonrelevant Financial Relationship/Chair, CLL). Supported by the NIH/NCI under award number P30 CA016672 and used MDACC Cancer Center Support Grant (CCSG) shared resources; Miragen: Research Funding; Oncternal Therapeutics, Inc.: Research Funding; Janssens Biotech: Research Funding; Accutar Biotechnology: Research Funding; Sunesis: Research Funding; KITE Pharma: Research Funding; Bristol Myers Squibb (Juno & Celgene): Consultancy, Research Funding; Gilead Sciences: Research Funding; AstraZeneca/Acerta Pharma: Consultancy, Research Funding; Genentech: Research Funding; Pharmacyclics LLC: Research Funding; GSK/Novartis: Research Funding. Shah: Umoja: Consultancy; Janssen: Consultancy; BMS/Juno: Consultancy, Tundra Therapeutics: Current holder of stock options in a privately-held company; LOXO-Lilly: Consultancy, Other: Travel support; Epizyme: Consultancy; TG Therapeutics: Consultancy; Novartis: Consultancy; Seattle Genetics: Consultancy; Gilead/Kite: Consultancy; Incyte: Consultancy; Abbvie: Consultancy; Lilly Oncology: Consultancy, Research Funding; Miltenyi Biotec: Consultancy, Other: Travel support, Research Funding. Cheah: Roche: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: TRAVEL, ACCOMMODATIONS, EXPENSES, Research Funding; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; MSD: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Gilead: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Ascentage Pharma: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; AstraZeneca: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Lilly: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; TG Therapeutics: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; BeiGene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; BMS: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; AbbVie: Research Funding; Menarini: Consultancy, Honoraria; Genmab: Consultancy, Honoraria; Daizai: Consultancy, Honoraria. Lewis: Kite: Consultancy, Membership on an entity's Board of Directors or advisory committees; BeiGene: Consultancy, Membership on an entity's Board of Directors or advisory committees; Roche: Consultancy, Membership on an entity's Board of Directors or advisory committees; Lilly: Consultancy, Membership on an entity's Board of Directors or advisory committees; Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees;
committees. **Hoffmann:** Pharmacycics LLC, an AbbVie Company: Consultancy, Honoraria. **Coombs:** Loxo Oncology/Eli Lilly and Company: Consultancy, Honoraria, Research Funding; **BeiGene:** Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; **AstraZeneca:** Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; **TG Therapeutics:** Honoraria; **MEI Pharma:** Honoraria; **Mingsight:** Honoraria; **Genentech:** Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; **Janssen:** Honoraria; **Bluebird Bio:** Current equity holder in publicly-traded company; **AbbVie:** Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; **Octapharma:** Consultancy. **Lamanna:** Genentech: Consultancy, Research Funding; **Pharmacycics:** Consultancy; **TG Therapeutics:** Research Funding; **BeiGene:** Consultancy, Research Funding; **AstraZeneca:** Consultancy, Research Funding; **Abbvie:** Consultancy, Research Funding; **MingSight:** Research Funding; **Eli Lilly/Loxo:** Research Funding; **Adaptive Biotechnologies:** Consultancy; **Janssen:** Consultancy; **Oncternal:** Research Funding; **Octapharma:** Research Funding. **Ma:** AstraZeneca: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; **Abbvie:** Consultancy, Research Funding; **Genentech:** Consultancy; **Janssen Pharmaceuticals:** Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; **Eli Lilly and Company/Loxo Oncology:** Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; **BeiGene:** Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau. **Jagadeesh:** Seagen: Research Funding; **Trillium Pharmaceuticals:** Research Funding; **Regeneron Pharmaceuticals:** Research Funding; **MEI Pharma:** Research Funding, LOXO Pharmaceuticals: Research Funding; **Debio Pharma:** Research Funding; **ATARA Biotherapeutics:** Research Funding; **AstraZeneca:** Research Funding; **Affimed:** Membership on an entity's Board of Directors or advisory committees; **Daiichi Sankyo:** Membership on an entity's Board of Directors or advisory committees. **Munir:** BeiGene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; **Alexion:** Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; **Sobi:** Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; **Roche:** Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; **AstraZeneca:** Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; **Janssen:** Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; **Abbvie:** Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau. **Wang:** Novartis: Research Funding; **Genentech:** Research Funding; **TG Therapeutics:** Membership on an entity's Board of Directors or advisory committees; **Genmab:** Research Funding; **Kite:** Honoraria, Membership on
an entity's Board of Directors or advisory committees; Morphosys: Research Funding; LOXO Oncology: Membership on an entity's Board of Directors or advisory committees, Research Funding; Incyte: Membership on an entity's Board of Directors or advisory committees, Research Funding; Innocare: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Membership on an entity's Board of Directors or advisory committees; Eli Lilly: Membership on an entity's Board of Directors or advisory committees, Research Funding; BeiGene: Membership on an entity's Board of Directors or advisory committees; AstraZeneca: Membership on an entity's Board of Directors or advisory committees; AbbVie: Consultancy. Eyre: Loxo Lilly: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Eli Lilly and Company: Consultancy, Honoraria, Speakers Bureau; Incyte: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; BeiGene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Autolus: Consultancy; AstraZeneca: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; KITE: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; Abbvie: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Loxo Oncology: Consultancy, Honoraria, Other, Speakers Bureau; Roche: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Medscape: Speakers Bureau; Janssen: Consultancy, Honoraria, Speakers Bureau; Gilead: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; PeerView: Speakers Bureau; Secura Bio: Membership on an entity's Board of Directors or advisory committees. Rhodes: Pharmacyclics: Consultancy, Research Funding; Janssen: Consultancy; Genentech: Consultancy; Velosbio: Research Funding; Loxo Oncology: Research Funding; Acerta: Research Funding, Oncternal Pharmaceuticals: Research Funding; SeaGen: Honoraria; GenMab: Consultancy, AstraZeneca: Consultancy; Morphosys: Consultancy; ADC Therapeutics: Consultancy; Epizyme: Consultancy, Research Funding; BeiGene: Consultancy; Abbvie: Consultancy, Research Funding. McKinney: Bayer, ADC therapeutics, Epizyme, Genentech, Inc. / F. Hoffmann-La Roche Ltd, Incyte: Consultancy; BeiGene, Janssen, F. Hoffmann-La Roche Ltd / Genentech, Inc., Celgene/BMS, Incyte: Research Funding; ADC therapeutics, BeiGene, Kite/Gilead: Speakers Bureau. Tam: AbbVie: Honoraria, Research Funding; Janssen: Honoraria, Research Funding; BeiGene: Honoraria, Research Funding; LOXO: Honoraria; Novartis: Honoraria; Roche: Honoraria. Jurczak: AbbVie: Consultancy, AstraZeneca: Consultancy; BeiGene: Consultancy; Eli Lilly: Consultancy; Pfizer: Consultancy, Roche: Consultancy; SOBI: Consultancy; Takeda: Consultancy; AbbVie: Research Funding; AstraZeneca: Research Funding; Bayer: Research Funding; BeiGene: Research Funding; Celgene: Research Funding; Janssen: Research Funding; Eli Lilly: Research Funding; Merck: Research Funding.
Funding; Pfizer: Research Funding; Roche: Research Funding; SOBI: Research Funding; Takeda: Research Funding. Izutsu: Eli Lilly: Honoraria; SymBio Pharmaceuticals: Honoraria; Meiji Seika: Honoraria; Nihon Kayaku: Honoraria; Takeda: Consultancy, Honoraria; AstraZeneca: Consultancy, Honoraria, Research Funding; Janssen: Honoraria; Genmab: Consultancy, Honoraria, Research Funding; MSD: Honoraria, Research Funding; Pfizer: Honoraria, Research Funding; Chugai Pharma: Honoraria, Research Funding; Kyowa Kirin: Honoraria, Research Funding; Zenyaku Kogyo: Consultancy; Mitsubishi Tanabe Pharma: Consultancy; Nippon Shinyaku: Consultancy; Astellas Amgen: Research Funding; Incyte: Research Funding; Bristol Myers Squibb: Honoraria, Research Funding; Novartis: Honoraria, Research Funding; Yakult: Research Funding; Daiichi Sankyo: Honoraria, Research Funding; Beigene: Research Funding; Loxo Oncology: Research Funding; Regeneron: Research Funding; Ono Pharmaceuticals: Consultancy, Honoraria; Eisai: Consultancy, Honoraria, Research Funding; Otsuka: Consultancy, Research Funding; Abbvie: Consultancy, Honoraria, Research Funding. Alencar: Genentech: Membership on an entity's Board of Directors or advisory committees; Lilly: Membership on an entity's Board of Directors or advisory committees, Research Funding; Amgen: Membership on an entity's Board of Directors or advisory committees; TG Therapeutics: Membership on an entity's Board of Directors or advisory committees; Incyte: Membership on an entity's Board of Directors or advisory committees, Research Funding; Beigene: Membership on an entity's Board of Directors or advisory committees, Research Funding; Vara: Membership on an entity's Board of Directors or advisory committees; Epizyme: Membership on an entity's Board of Directors or advisory committees; SeaGen: Membership on an entity's Board of Directors or advisory committees; Dr Reddy: Honoraria. Patel: Janssen Oncology: Honoraria; Olema Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees; ION Pharmaceuticals: Other: Leadership. Seymour: Genor Bio: Membership on an entity's Board of Directors or advisory committees; Hoffmann-La Roche: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; F. Hoffmann-La Roche Ltd: Research Funding; TG Therapeutics: Consultancy; AbbVie: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; AstraZeneca: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; BMS: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Gilead: Honoraria, Membership on an entity's Board of Directors or advisory committees; Beigene: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Woyach: Newave: Consultancy; Loxo: Consultancy; Beigene: Consultancy; AstraZeneca: Consultancy; Abbvie: Consultancy; Schrodingers: Research Funding; Morphosys: Research Funding; Karyopharm: Research Funding; Janssen: Consultancy, Research Funding; Pharmacypcics: Consultancy, Research Funding. Roeker: Beigene: Consultancy; Ascentage: Consultancy; Qilu Puget Sound Biotherapeutics: Research
Funding; **AbbVie**: Consultancy, Research Funding; **Curio**: Other: CME speaker; **Abbott Laboratories**: Current equity holder in publicly-traded company; **Medscape**: Other: CME speaker; **Janssen**: Consultancy; **AstraZeneca**: Consultancy, Research Funding; ** Therapeutics**: Consultancy; **Loxo Oncology**: Consultancy, Other: travel support, Research Funding; **Dren Bio**: Research Funding; **Adaptive Biotechnologies**: Research Funding; **Genentech**: Research Funding; **Aptose Biosciences**: Research Funding; **Pharmacyclics**: Consultancy; **Pfizer**: Consultancy, Research Funding; **TG Therapeutics**: Consultancy; **Loxo Oncology**: Consultancy, Other: travel support, Research Funding; **Dren Bio**: Research Funding; **Adaptive Biotechnologies**: Consultancy, Research Funding; **Genentech**: Research Funding; **Aptose Biosciences**: Research Funding; **Pharmacyclics**: Consultancy; **Pfizer**: Consultancy, Research Funding; **DAVA**: Other: CME speaker; **PeerView**: Other: CME speaker. **Thompson**: beigene: Consultancy; **astrazeneca**: Consultancy, Speakers Bureau; **genentech**: Consultancy; **janssen**: Consultancy, Speakers Bureau; **Lilly**: Consultancy; **merck**: Consultancy, Speakers Bureau; **pharmacyclics**: Consultancy; **adaptive biotechnologies**: Consultancy, Research Funding, Speakers Bureau; **abbvie**: Consultancy. **Abada**: Eli Lilly and Company: Current Employment, Current equity holder in publicly-traded company. **Ho**: Eli Lilly and Company: Current equity holder in publicly-traded company; **Loxo@Lilly**: Current Employment. **Marella**: Eli Lilly and Company: Current equity holder in publicly-traded company; **Loxo@Lilly**: Current Employment. **Wang**: Eli Lilly and Company: Current Employment, Current equity holder in publicly-traded company. **Ruppert**: Eli Lilly and Company: Current Employment, Current equity holder in publicly-traded company; **Telios Pharma**: Consultancy. **Chandrakekharan Nair**: Loxo@Lilly: Current Employment; Eli Lilly and Company: Current equity holder in publicly-traded company. **Liu**: Loxo@Lilly: Current Employment. **Tsai**: Eli Lilly and Company: Current Employment. **Ghia**: Janssen: Consultancy, Honoraria, Research Funding; Lilly/Loxo Oncology: Consultancy, Honoraria, Research Funding; **MSD**: Consultancy, Honoraria, Research Funding; **Roche**: Consultancy, Honoraria, Research Funding; **AbbVie**: Consultancy, Honoraria, Research Funding; **BMS**: Consultancy, Honoraria, Research Funding; **BeiGene**: Consultancy, Honoraria, Research Funding; **AstraZeneca**: Consultancy, Honoraria, Research Funding.
202 Extended Follow-up of ALPINE Randomized Phase 3 Study Confirms Sustained Superior Progression-Free Survival of Zanubrutinib Versus Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL)

Program: Oral and Poster Abstracts
Type: Oral
Session: 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Analysis and Treatment of High Risk and Treatment of Relapsed CLL or Richter Transformation
Hematology Disease Topics & Pathways:
Lymphoid Leukemias, CLL, Disease, Lymphoid Malignancies

Saturday, December 9, 2023: 2:45 PM

Jennifer R. Brown, MD, PhD, Barbara F. Eichhorst, MD, Nicole Lamanna, MD, Susan M. O’Brien, Constantine S. Tam, MD, MBBS, Luqui Qiu, Maciej Kazmierczak, MD, Wojciech Jurczak, MD, PhD, Keshu Zhou, MD, Martin Simkovic, MD, Jiri Mayer, MD, Amanda L. Gillespie-Twardy, MD, Alessandra Ferrajoli, MD, Peter S. Ganly, PhD, Robert Weinkove, MBBS, PhD, FRACP, FRCPA, Sebastian Grosicki, MD, PhD, Andrzej Mital, Tadeusz Robak, Anders Osterborg, MD, PhD, Habte A. Yimer, MD, Megan (Der Yu) Wang, Tommi Salmi, MD, Liping Wang, Jessica Li, MSc, Kenneth Wu, Aileen Cleary Cohen, MD, PhD, and Mazyar Shadman, MD, MPH

1Chronic Lymphocytic Leukemia Center, Division of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA
2Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf German CLL Study Group University of Cologne, University Hospital Cologne, Cologne, Germany
3Herbert Irving Comprehensive Cancer Center, Columbia University, New York
4Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, CA
5Alfred Hospital and University of Melbourne, Melbourne, VIC, Australia
6State Key Laboratory of Experimental Hematology, National Clinical Research Center for Hematological Disorders, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, CHN
7Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Krakow, Poland
8Dpt of Clinical Oncology, MSC National Research Institute of Oncology, Kraków, Poland
9Department of Hematology, Cancer Hospital Affiliated to Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China
104th Department of Internal Medicine – Haematology, Faculty of Medicine in Hradec Králové, University Hospital and Charles University in Prague, Hradec Královo, Czech Republic
Introduction: ALPINE, a randomized, multinational phase 3 study (NCT03734016) in patients with R/R CLL/SLL, established the statistical and clinically meaningful superiority of zanubrutinib over ibrutinib on progression-free survival (PFS) and overall response rate (ORR) and confirmed the favorable safety/tolerability profile of zanubrutinib (Brown et al. NEJM; 2022). Now, with 3 years of overall study follow-up, we report the results of an extended follow-up analysis.

Methods: As previously published, patients with R/R CLL/SLL who had received ≥1 prior therapy and had measurable disease were randomized 1:1 to receive zanubrutinib or ibrutinib. Efficacy assessments, including PFS and ORR, were evaluated by the investigator based on 2008 iwCLL criteria; sensitivity analyses to confirm PFS results were also conducted. Updated safety analyses were performed. All reported P-values are descriptive.

Results: Overall, 652 patients were randomized to receive zanubrutinib (n=327) or ibrutinib (n=325). As of 15 May 2023, 63.3% (n=207/327) of patients remain on zanubrutinib and 52.3% (n=170/325) remain on ibrutinib. At a median study follow-up of 36.3 months, benefit of zanubrutinib over ibrutinib was sustained (HR: 0.67 [95% CI, 0.52-0.86]; 2-sided P=.002; Fig 1). At 36 months, the PFS rates were 65.8% with zanubrutinib and 54.3% with ibrutinib. Benefits in PFS with zanubrutinib were also observed across major subgroups, including in patients with del(17p)/TP53 mutations (HR: 0.52 [95% CI, 0.32-0.83] 2-sided P=.005) where 36-month PFS rates were 60.1% and 43.6%, respectively. Additionally, the zanubrutinib PFS benefit was confirmed in a sensitivity analysis that included only progression and death events that occurred on active treatment (HR: 0.69 [95% CI, 0.49-0.97]; 2-sided P=.031). ORR remained higher with zanubrutinib compared with ibrutinib (85.0% vs 74.8%; 2-
sided \( P=.001 \). Responses deepened in both arms with CR/CRi rates of 10.1% (zanubrutinib) and 7.4% (ibrutinib); the rate of PR-L or better was 90.2% vs 82.8%, respectively. Fifty-nine (18.0%) patients treated with zanubrutinib and 71 (21.8%) treated with ibrutinib had died (OS HR: 0.76 [95% CI, 0.54-1.08]); 36-month OS rates were 82.6% (zanubrutinib) and 79.7% (ibrutinib).

In this extended follow-up, median treatment duration was 34.7 months (zanubrutinib) and 31.5 months (ibrutinib). Across both arms, the most common reasons for treatment discontinuation were AEs (20.2%, zanubrutinib; 24.9%, ibrutinib) and progressive disease (12.2%, zanubrutinib; 16.3%, ibrutinib). Dose interruption and dose reduction due to AEs were 59.6% vs 61.1% and 14.2% vs 17.6% with zanubrutinib vs ibrutinib, respectively.

The most common AEs of any grade with zanubrutinib and ibrutinib were COVID-19 (37.3% vs 25.6%), diarrhea (17.9% vs 25.6%), and upper respiratory tract infection (25.9% vs 17.3%). Rates of any grade ≥3 AEs and serious AEs were 72.2% vs 75.6% and 49.7% vs 57.4% with zanubrutinib vs ibrutinib, respectively. Most commonly reported grade ≥3 AEs were neutropenia (17.3% vs 16.4%) and hypertension (15.1% vs 12.0%). Rates of serious infections were 30.6% in each treatment arm. Discontinuation rates due to cardiac disorders were lower with zanubrutinib (0.6% [n=2]) vs ibrutinib (4.6% [n=15]). Overall cardiac events remain lower with zanubrutinib, including atrial fibrillation/flutter (6.2% vs 16.0%; 2-sided \( P<.0001 \)). Across this study, no grade 5 AEs due to cardiac disorders were observed with zanubrutinib but were reported in 6 patients (1.9%) with ibrutinib (Table 1).

**Conclusions:** ALPINE was the first study to demonstrate PFS superiority in a head-to-head comparison of BTK inhibitors. At a median follow-up of 3 years, the study showed sustained PFS benefits of zanubrutinib over ibrutinib. The durable PFS benefits with zanubrutinib were observed across major subgroups, including multiple sensitivity analyses. The overall safety/tolerability profiles were consistent with previous reports for both treatments. The cardiac safety profile remained favorable for zanubrutinib compared with ibrutinib, with no new safety signals emerging with longer follow-up. With over 3 years of treatment, zanubrutinib continues to be a more efficacious and better tolerated treatment than ibrutinib for patients with R/R CLL/SLL. At time of presentation, data with further follow-up will be presented.
Disclosures: Brown: Loxo/Lilly: Consultancy, Research Funding; TG Therapeutics: Research Funding; Pharmacyclics: Consultancy; Numab Therapeutics: Consultancy; Merck: Consultancy; Gilead: Research Funding; Grifols Worldwide Operations: Consultancy; Kite: Consultancy; BeiGene: Consultancy, Research Funding; iOnctura: Consultancy, Research Funding; SecuraBio: Research Funding; Alloplex
Biotherapeutics: Consultancy; Hutchmed: Consultancy; MEI Pharma: Research Funding; Pfizer: Consultancy; Genentech/Roche: Consultancy; Abbvie: Consultancy; Acerta/AstraZeneca: Consultancy. **Eichhorst**: Janssen: Consultancy, Research Funding, Speakers Bureau; Lilly: Consultancy, Speakers Bureau; MSD: Consultancy, Honoraria, Speakers Bureau; F. Hoffmann-La Roche Ltd: Honoraria, Research Funding, Speakers Bureau; Genentech: Consultancy, Honoraria, Research Funding, Speakers Bureau; Gilead: Consultancy, Research Funding; Abbvie: Consultancy, Honoraria, Research Funding, Speakers Bureau; AstraZeneca: Consultancy, Honoraria, Research Funding, Speakers Bureau. **Lamanna**: Abbvie: Consultancy, Research Funding; Pharmacyclics: Consultancy; Octapharma: Research Funding; Eli Lilly/Loxo: Research Funding; Genentech: Consultancy, Research Funding; Janssen: Consultancy; AstraZeneca: Consultancy, Research Funding; Adaptive Biotechnologies: Consultancy; TG Therapeutics: Research Funding; Oncternal: Research Funding; MingSight: Research Funding; BeiGene: Consultancy, Research Funding. **O’Brien**: Johnson & Johnson: Consultancy; Janssen: Consultancy; Lilly: Consultancy, Research Funding; Beigene: Consultancy, Research Funding; AstraZeneca: Consultancy; Abbvie: Consultancy; Pfizer: Consultancy, Research Funding; Regeneron: Research Funding; Pharmacyclics: Consultancy, Research Funding. **Tam**: AbbVie: Honoraria, Research Funding; Janssen: Honoraria, Research Funding; BeiGene: Honoraria, Research Funding; LOXO: Honoraria; Novartis: Honoraria; Roche: Honoraria. **Qiu**: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences: Current Employment; BeiGene, Janssen, Roche, AstraZeneca, Takeda: Speakers Bureau. **Jurczak**: AstraZeneca: Consultancy; AbbVie: Consultancy; BeiGene: Consultancy; Eli Lilly: Consultancy; Pfizer: Consultancy; Roche: Consultancy; SOBI: Consultancy; Takeda: Consultancy; AbbVie: Research Funding; AstraZeneca: Research Funding; Bayer: Research Funding; BeiGene: Research Funding; Celgene: Research Funding; Janssen: Research Funding; Eli Lilly: Research Funding; Merck: Research Funding; Pfizer: Research Funding; Roche: Research Funding; SOBI: Research Funding; Takeda: Research Funding. **Simkovic**: 4th Department of Internal Medicine-Haematology, Faculty of Medicine in Hradec Králové, University Hospital and Charles University in Prague, Hradec Králové, Czech Republic: Current Employment; AbbVie, AstraZeneca, Janssen-Cilag: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees; AbbVie, AstraZeneca, J&J, Beigene, Gilead, Baxter, Novartis, Abbot, Sanofi, Merck, GSK, Sanofi, Vertex, Eli Lilly, Genmab: Current equity holder in publicly-traded company. **Mayer**: BeiGene: Research Funding; Ferrajoli: Genetech: Honoraria; GenMab: Research Funding; Beigene: Research Funding; Janssen: Honoraria; AstraZeneca: Honoraria, Research Funding; Abbvie: Honoraria, Research Funding; Weinkove: Fisher & Paykel Healthcare: Current equity holder in publicly-traded company; BioOra: Research Funding; BeiGene: Honoraria; Janssen: Honoraria, Research Funding; AbbVie: Honoraria. **Robak**: BeiGene: Honoraria, Research Funding; AstraZeneca: Honoraria, Research Funding; Regeneron: Honoraria, Research Funding; GSK: Honoraria, Research Funding.
Funding; Janssen: Consultancy, Honoraria, Research Funding; OctoPharma: Honoraria, Research
Funding; Abbvie: Honoraria. Yimer: Abbvie, Amgen, AstraZeneca, BeiGene USA, Inc., GlaxoSmithKline, Janssen
equity holder in publicly-traded company. Salmi: BeiGene: Current Employment, Current equity holder in
equity holder in publicly-traded company. Wu: BeiGene: Current Employment, Current equity holder in publicly-
traded company. Cohen: BeiGene: Current Employment, Current equity holder in publicly-traded
company, Divested equity in a private or publicly-traded company in the past 24
months. Shadman: BeiGene: Consultancy, Research Funding; Mustang Bio: Consultancy, Research
Funding; ADC therapeutics: Consultancy; Vincerx: Research Funding; Eli
Lilly: Consultancy; Genmab: Consultancy, Research Funding; Kite, a Gilead Company: Consultancy; Bristol Myers
Squibb: Consultancy, Research Funding; Genentech: Consultancy, Research
Funding; AbbVie: Consultancy, Research Funding; Pharmacyclics: Consultancy, Research
Funding; MorphoSys/Incyte: Consultancy, Research Funding; MEI Pharma: Consultancy; Fate
Therapeutics: Consultancy; Janssen: Consultancy; AstraZeneca: Consultancy, Research
Funding; Regeneron: Consultancy; TG Therapeutics: Research Funding.
325 Pirtobrutinib in Post-cBTKi CLL/SLL: ~30 Months Follow-up and Subgroup Analysis With/Without Prior BCL2i from the Phase 1/2 BRUIN Study

Program: Oral and Poster Abstracts
Type: Oral
Session: 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: New Inhibitors and Cellular Therapies for Treatment of Relapsed CLL
Hematology Disease Topics & Pathways:
Research, clinical trials, Lymphoid Leukemias, CLL, Clinical Research, Diseases, Lymphoid Malignancies
Saturday, December 9, 2023: 4:00 PM

Jennifer A. Woyach, MD1, Jennifer R. Brown, MD, PhD2, Paolo Ghia, MD, PhD3, Lindsey E. Roeker, MD4, Krish Patel, MD4, Toby A. Eyre4, Talha Munir, MBBS, MRCP, FRCPath, PhD5, Ewa Lech-Maranda, MD, PhD6, Nicole Lamanna, MD7, Constantine S. Tam, MD, MBBS10, John F. Seymour, MBBS, PhD, FRACP11, Benoit Tessoulin12, Nirav N. Shah, MD13, Chaitra S Ujjani, MD14, Bita Fakhri, MD, MPH15, Catherine C. Coombs, MD16, Ian W. Flinn, MD, PhD17, Manish Patel, MD18, Sunita D. Nasta, MD19, Jonathon B. Cohen, MD, MS20, Alvaro J. Alencar, MD21, Chan Y. Cheah, MD, DMSc22, Shuo Ma, MD, PhD23, Joanna M. Rhodes, MD, MSCE24, Deepa Jagadeesh, MD25, Pier Luigi Zinzani, MD, PhD26, Anders Österborg, MD, PhD27, Koji Izutsu, MD, PhD28, Donald E. Tsai, MD, PhD29, Paolo Abada, MD29, Minna Balbas, PhD29, Jian Li, MS29, Amy S. Ruppert, PhD29, Wojciech Jurczak, MD, PhD29 and William G. Wierda, MD, PhD29

1 The Ohio State University Comprehensive Cancer Center, Columbus, OH
2 Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA
3 Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milano, Italy
4 Memorial Sloan Kettering Cancer Center, New York, NY
5 Swedish Cancer Institute, Seattle, WA
6 Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Center, Oxford, United Kingdom
7 Department of Haematology, St. James’s University Hospital, Leeds, United Kingdom
8 Institute of Hematology and Transfusion Medicine, Warsaw, Poland
9 Herbert Irving Comprehensive Cancer Center, Columbia University, New York
10 Alfred Health and Monash University, Melbourne, VIC, Australia
11 Peter MacCallum Cancer Center, Royal Melbourne Hospital and University of Melbourne, Melbourne, VIC, Australia
12 Hematology Department, University Hospital, Nantes, France
13 Medical College of Wisconsin, Milwaukee, WI
14 Fred Hutchinson Cancer Research Center, Seattle, WA
15 Stanford University School of Medicine, Stanford, CA
16 University of California Irvine, Irvine, CA
Background: The treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has benefited from covalent (c) Bruton tyrosine kinase inhibitors (BTKi), however, therapy can fail due to progression or intolerance. Sequential treatment with B-cell lymphoma 2 protein inhibitor (BCL2i) venetoclax, either as monotherapy or combined with an anti-CD20 monoclonal antibody, has been the primary treatment option for CLL/SLL patients (pts) whose disease has progressed on cBTKi. Pirtobrutinib is a highly selective, non-covalent (reversible) BTKi that demonstrated promising efficacy in patients with relapsed or refractory CLL/SLL (Mato et al, NEJM, 2023). Here, we report on the efficacy of pirtobrutinib treatment in CLL/SLL in the post-cBTKi setting, including subgroups with or without prior BCL2i, using data from the BRUIN study (NCT03740529) with more than 2 years follow-up.

Methods: Pts with previously treated CLL/SLL were eligible for treatment with pirtobrutinib in the multicenter Phase 1/2 BRUIN study. Key endpoints included ORR (including partial response with lymphocytosis; PR-L) as assessed by an independent review committee per 2018 iwCLL response criteria, DoR, PFS, OS, and safety. A data cut of 05MAY2023 was utilized.

Results: In total, 282 pts with CLL/SLL who received prior cBTKi were included in this analysis. Median age was 69 years (range, 36-88), 68% were male, and median number of prior therapies was 4 (range, 1-11). Of 282 pts, 154 (55%) had not received prior-BCL2i therapy (Naïve; BCL2i-N) and 128 (45%) had (Exposed; BCL2i-E). BCL2i-N pts were exposed to fewer prior therapies than BCL2i-E pts (median prior therapies 3 and 5, respectively), including anti-CD20 antibody (83% and 97%), chemotherapy (74% and 89%), PI3K inhibitor (11% and 42%), CAR-T cell therapy (1% and 12%), and hematopoietic cell transplantation (1% and 6%). The ORR for all post-cBTKi pts was 72% (95% CI, 66.4-77.1), and ORR including PR-L was 82% (95% CI, 76.5-85.9). Post-cBTKi pts included
a subgroup of 19 pts with one prior line of cBTKi-containing therapy and second line therapy of pirtobrutinib, who had ORR including PR-L of 89.5\% (CI 95\%, 66.9-98.7). The ORR including PR-L was 83.1\% (95\% CI, 76.2-88.7) for BCL2i-N pts, and 79.7\% (95\% CI, 71.7-86.3) for BCL2i-E pts. Median DoR was 18.4 months (95\% CI, 15.3-20.4) for all cBTKi pre-treated pts, 24.9 months (95\% CI, 18.4-32.0) for BCL2i-N, and 14.8 months (95\% CI, 12.0-17.4) for BCL2i-E. With a median follow up of 27.5 months, the median PFS was 19.4 months (95\% CI, 16.6-22.1) among all cBTKi pre-treated pts, 23.0 months (95\% CI, 19.6-28.4) for BCL2i-N, and 15.9 months (95\% CI, 13.6-17.5) for BCL2i-E (Figure). With a median follow up of 29.3 months, the median OS was not estimable for all cBTKi pre-treated pts, BCL2i-N, and BCL2i-E; the 24-month OS rates were 73.2\% (95\% CI, 67.4-78.2), 83.1\% (95\% CI, 75.9-88.2), 60.6\% (50.9-68.9), respectively.

In the CLL/SLL cohort (N=282), the most frequent treatment-emergent adverse events (TEAE), regardless of attribution, were fatigue (36.9\%), diarrhea (28.4\%), cough (27.3\%) and contusion (26.2\%). The most frequent Grade ≥3 TEAE was neutropenia/neutrophil count decreased (28.4\%). Grade ≥3 TEAEs of hypertension (4.3\%) and atrial fibrillation/flutter (1.8\%) were infrequent. The AE profile of BCL2i-N and BCL2i-E pts was overall similar. Though Grade ≥3 neutropenia/neutrophil count decreased was higher in BCL2i-E pts (36.7\% and 21.4\%), this may have been attributed to the higher frequency of baseline neutropenia in BCL2i-E pts (27.3\% and 11.0\%). In total, 7 (2.5\%; 4 BCL2i-N, 3 BCL2i-E) pts had treatment-related AE leading to pirtobrutinib discontinuation.

**Conclusion:** Pirtobrutinib continues to demonstrate promising and durable efficacy in pts with post-cBTKi heavily pretreated CLL/SLL. ORR was high regardless of prior BCL2i status. Longer PFS was observed in BCL2i-N pts than BCL2i-E pts, likely due to the more heavily pretreated status of the BCL2i-E population which can be associated with poorer prognosis. Pirtobrutinib was well-tolerated with low-rates of discontinuation due to drug-related toxicity among both BTKi-N and BTKi-E pts. These results suggest that continuation of BTK pathway inhibition following a cBTKi may be an important sequencing approach to consider in the treatment of CLL/SLL.
**Disclosures: Woyach:** AbbVie Inc, Karyopharm Therapeutics, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MingSight Pharmaceuticals, MorphoSys, Schrödinger, Verastem Inc.: Other: Contracted Research; AbbVie Inc, ArQule Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Genentech, a member of the Roche Group, Janssen Biotech Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Newave Pharmaceutical Inc, Pharmacyclics LLC, an AbbVie: Other: Advisory Committee and Consulting Agreements. **Brown:** SecuraBio: Research Funding; MEI Pharma: Research Funding; Hutchmed: Consultancy; Grifols Worldwide

**Operations:** Consultancy; Pfizer: Consultancy; Kite: Consultancy; Numab

**Therapeutics:** Consultancy; Merck: Consultancy; Loxo@Lilly: Consultancy, Research Funding; iOnctura: Consultancy, Research Funding; TG Therapeutics: Research Funding; Alloplex

**Biotherapeutics:** Consultancy; BeiGene: Consultancy, Research Funding; Genentech/Roche: Consultancy; Pharmacyclics: Consultancy; Gilead: Research Funding; Acerta/AstraZeneca: Consultancy, AbbVie: Consultancy. **Ghia:** Roche: Consultancy, Honoraria, Research Funding; BeiGene: Consultancy, Honoraria, Research Funding; BMS: Consultancy, Honoraria, Research Funding; Lilly/Loxo Oncology: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Research Funding; MSD: Consultancy, Honoraria, Research Funding; AstraZeneca: Consultancy, Honoraria, Research Funding; AbbVie: Consultancy, Honoraria, Research Funding. **Roeker:** Loxo Oncology: Consultancy, Other: travel support, Research Funding; Medscape: Other: CME speaker; Adaptive Biotechnologies: Research Funding; Curio: Other: CME speaker; DAVA: Other: CME speaker; PeerView: Other: CME speaker; Aptose Biosciences: Research Funding; Genentech: Research Funding; Janssen: Consultancy; Ascentage: Consultancy; AstraZeneca: Consultancy, Research Funding; BeiGene: Consultancy; Pharmacyclics: Consultancy; Pfizer: Consultancy, Research Funding; TG Therapeutics: Consultancy; Dren Bio: Research Funding; Qilu Puget Sound Biotherapeutics: Research Funding; Abbott Laboratories: Current equity holder in publicly-traded company; AbbVie: Consultancy, Research Funding. **Patel:** Abbvie: Consultancy; Fate Therapeutics: Research Funding; AstraZeneca: Consultancy, Research Funding, Speakers Bureau; Curis, Inc: Research Funding; Xencor: Consultancy, Research Funding; Morphosys: Consultancy; Merck: Consultancy, Research Funding; MEI Pharma: Consultancy, Research Funding; Loxo Oncology: Consultancy, Research Funding; Kite: Consultancy, Research Funding, Speakers Bureau; Genentech/Roche: Consultancy, Research Funding; Epizyme: Consultancy, Research Funding; CRISPR Therapeutics: Research Funding; Caribou Biosciences: Consultancy; Bristol Myers Squibb: Consultancy, Research Funding, Speakers Bureau; BeiGene: Consultancy; ADC Therapeutics: Consultancy; Nurix: Research Funding; Pharmacyclics/Janssen: Consultancy, Research Funding; Sunesis Pharmaceuticals: Research Funding; TG Therapeutics: Consultancy, Speakers Bureau; Trillium Therapeutics/Pfizer: Consultancy, Research Funding; Adaptive Biotechnologies: Research Funding. **Eyre:** Autolus: Consultancy; Eli Lilly and Company: Consultancy, Honoraria, Speakers Bureau; **KITE:** Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory
committees, Speakers Bureau; **Loxo Oncology**: Consultancy, Honoraria, Other, Speakers Bureau; **Incyte**: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; **Janssen**: Consultancy, Honoraria, Speakers Bureau; **Abbvie**: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; **Beigene**: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; **AstraZeneca**: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; **Gilead**: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; **Loxo Lilly**: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; **PeerView**: Speakers Bureau; **Medscape**: Speakers Bureau; **SecuraBio**: Membership on an entity's Board of Directors or advisory committees; **Roche**: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. **Munir**: **Beigene**: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; **Alexion**: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; **Abbvie**: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; **Sobi**: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; **Roche**: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; **AstraZeneca**: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; **Janssen**: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; **Abbvie**: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau. **Lamanna**: **Abbvie**: Consultancy, Research Funding; **Octapharma**: Research Funding; **Janssen**: Consultancy; **Oncternal**: Research Funding; **MingSight**: Research Funding; **Eli Lilly/Loxo**: Research Funding; **Pharmacyclics**: Consultancy; **Adaptive Biotechnologies**: Consultancy; **TG Therapeutics**: Research Funding; **Genentech**: Consultancy, Research Funding; **BeiGene**: Consultancy, Research Funding; **AstraZeneca**: Consultancy, Research Funding. **Tam**: **Janssen**: Honoraria, Research Funding; **AbbVie**: Honoraria, Research Funding. **Seymour**: **F. Hoffmann-La Roche Ltd**: Research Funding; **AstraZeneca**: Honoraria, Membership on an entity's Board of Directors or advisory committees; **Hoffmann-La Roche**: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; **Janssen**: Honoraria, Membership on an entity's Board of Directors or advisory committees; **AbbVie**: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; **TG Therapeutics**: Consultancy; **Gilead**: Honoraria, Membership on an entity's Board of Directors or advisory committees; **Beigene**: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; **BMS**: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; **Genor Bio**: Membership on an entity's Board of Directors or advisory committees;
committees. **Tessoulin**: Gilead: Honoraria; Abbvie: Honoraria; Incyte: Honoraria; Kite: Honoraria. **Shah**: Epizyme: Consultancy; Janssen: Consultancy; Novartis: Consultancy; TG Therapeutics: Consultancy; Umoja: Consultancy; LOXO-Lilly: Consultancy, Other: Travel support; Tundra Therapeutics: Current holder of stock options in a privately-held company; BMS/Juno: Consultancy; Seattle Genetics: Consultancy; Gilead/Kite: Consultancy; Incyte: Consultancy; Abbvie: Consultancy; Lilly Oncology: Consultancy, Research Funding; Miltenyi Biotec: Consultancy, Other: Travel support, Research Funding. **Ujjani**: Kite, a Gilead Company: Consultancy, Other: Travel expenses , Research Funding; Lilly: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria; Pharmacyclics: Consultancy, Honoraria, Research Funding; Genentech: Consultancy, Honoraria; Beigene: Consultancy, Honoraria; Abbvie: Consultancy, Honoraria, Research Funding; Atara: Consultancy; Epizyme: Consultancy, AstraZeneca: Consultancy, Honoraria, Research Funding; PCYC: Research Funding. **Fakhri**: Beigene: Consultancy, Membership on an entity's Board of Directors or advisory committees; AstraZeneca: Consultancy, Membership on an entity’s Board of Directors or advisory committees; ADC Therapeutics: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Abbvie: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Research Funding; BMS/Juno: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Genentech: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Genmab/Abbvie: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Research Funding; LOXO/Lilly: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Pharmacyclics: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Research Funding. **Coombs**: AbbVie, Genentech, Beigene, AstraZeneca, Lilly, Octapharma: Consultancy. **Flinn**: Genmab: Consultancy; BeiGene: Consultancy; Genentech: Consultancy, Secura Bio: Consultancy; Hutchinson MediPharma: Consultancy; Kite: Consultancy; Innocare Pharma: Consultancy; AbbVie: Consultancy; Novartis: Consultancy; Myeloid Therapeutics: Consultancy, Servier Pharma: Consultancy; Century Therapeutics: Consultancy; TG Therapeutics: Consultancy, Vincerx Pharma: Consultancy. **Patel**: ION Pharmaceuticals: Other: Leadership; Olema Pharmaceuticals: Membership on an entity’s Board of Directors or advisory committees; Janssen Oncology: Honoraria. **Nasta**: ADC Therapeutics: Honoraria; LOxo/Lilly: Research Funding; Millennium Takeda: Research Funding; Ono Pharmaceutical: Research Funding; Accrotech: Honoraria; Raphael: Research Funding; Pharmacyclics: Research Funding; Genentech/Roche: Research Funding; Merck-Data Safety Monitoring Committee: Membership on an entity’s Board of Directors or advisory committees. **Cohen**: BMS/Celgene: Research Funding; Novartis: Research Funding; Genentech: Research Funding; BiolInvent: Research Funding; Lam Therapeutics: Research Funding; Takeda: Research Funding; ADCT: Consultancy; AstraZeneca: Consultancy, Research Funding; Abbvie: Consultancy; Janssen: Consultancy; BeiGene: Consultancy, LOxo/Lilly: Consultancy, Research Funding. **Alencar**: Lilly: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Amgen: Membership on an entity’s Board of Directors or advisory committees; TG
**Therapeutics:** Membership on an entity's Board of Directors or advisory committees; **Incyte:** Membership on an entity's Board of Directors or advisory committees, Research Funding; **Beigene:** Membership on an entity's Board of Directors or advisory committees, Research Funding; **Janssen:** Membership on an entity's Board of Directors or advisory committees; **Epizyme:** Membership on an entity's Board of Directors or advisory committees; **SeaGen:** Membership on an entity's Board of Directors or advisory committees; **Dr Reddy:** Honoraria; **Genentech:** Membership on an entity's Board of Directors or advisory committees. **Cheah:** TG therapeutics: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; **Gilead:** Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; **AbbVie:** Research Funding; **Eli Lilly and Company:** Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; **AstraZeneca:** Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; **Novartis:** Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; **BMS:** Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; **BeiGene:** Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; **Ascentage Pharma:** Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: TRAVEL, ACCOMMODATIONS, EXPENSES, Research Funding; **Janssen:** Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; **Menarini:** Consultancy, Honoraria; **Genmab:** Consultancy, Honoraria; **Daizai:** Consultancy, Honoraria. **Ma:** Juno/BMS: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; **AstraZeneca:** Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; **Eli Lilly and Company/Loxo Oncology:** Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; **Genentech:** Consultancy, **AbbVie:** Consultancy, Research Funding; **Janssen Pharmaceuticals:** Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; **BeiGene:** Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau. **Rhodes:** Acerta: Research Funding; **Oncternal Pharmaceuticals:** Research Funding; **Loxo Oncology:** Research Funding; **SeaGen:** Consultancy; **GenMab:** Consultancy; **Epizyme:** Consultancy; **ADCT:** Consultancy; **Morphosys:** Consultancy; **AstraZeneca:** Consultancy; **Beigene:** Consultancy; **Pharmacyclics:** Consultancy, Research Funding; **Janssen:** Consultancy; **Genentech:** Consultancy; **AbbVie:** Consultancy, Research Funding; **Velosbio:** Research Funding; **Verastem:** Consultancy; **PCYC:** Consultancy. **Jagadeesh:** LOXO Pharmaceuticals: Research Funding; **ATARe Biotherapeutics:** Research Funding; **Debio Pharma:** Research Funding; **Regeneron Pharmaceuticals:** Research Funding; **Affimed:** Membership on an entity's Board of Directors or advisory committees; **Trillium Pharmaceuticals:** Research Funding; **Seagen:** Research Funding; **MEI**
**Pharma**: Research Funding; **AstraZeneca**: Research Funding; **Daiichi Sankyo**: Membership on an entity’s Board of Directors or advisory committees. **Zinzani**: **ASTRAZENECA**: Membership on an entity’s Board of Directors or advisory committees; **SANDOZ**: Membership on an entity’s Board of Directors or advisory committees; **CELLTRION**: Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; **MSD**: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; **SECURA BIO**: Membership on an entity’s Board of Directors or advisory committees; **GILEAD**: Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; **JANSSEN-CILAG**: Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; **BMS**: Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; **TAKEDA**: Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; **ROCHE**: Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; **SERVIER**: Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; **KYOWA KIRIN**: Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; **EUSAPHARMA**: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; **NOVARTIS**: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; **ADC THERAPEUTICS**: Membership on an entity’s Board of Directors or advisory committees; **INCYTE**: Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; **BEIGENE**: Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau. **Izutsu**: **Beigene**: Research Funding; **Takeda**: Consultancy, Honoraria; **Nippon**

**Shinyaku**: Consultancy; **Novartis**: Honoraria, Research Funding; **Bristol Myers Squibb**: Honoraria, Research Funding; **Mitsubishi Tanabe Pharma**: Consultancy; **Astellas Armg**: Research Funding; **Incyte**: Research Funding; **Loxo Oncology**: Research Funding; **Eli Lilly**: Honoraria; **SymBio**

**Pharmaceuticals**: Honoraria; **Regeneron**: Research Funding; **Eisai**: Consultancy, Honoraria, Research Funding; **Daiichi Sankyo**: Honoraria, Research Funding; **Genmab**: Consultancy, Honoraria, Research Funding; **AstraZeneca**: Consultancy, Honoraria, Research Funding; **Meiji Seika**: Honoraria; **Yakult**: Research Funding; **Janssen**: Honoraria; **Ono Pharmaceuticals**: Consultancy, Honoraria; **Nihon**

**Kayaku**: Honoraria; **MSD**: Honoraria, Research Funding; **Pfizer**: Honoraria, Research Funding; **Chugai Pharma**: Honoraria, Research Funding; **Kyowa Kirin**: Honoraria, Research Funding; **Zenyaku**

**Kogyo**: Consultancy; **Otsuka**: Consultancy, Research Funding; **Abbvie**: Consultancy, Honoraria, Research Funding. **Tsai**: **Loxo@Lilly**: Current Employment; **Eli Lilly and Company**: Current equity holder in publicly-traded company. **Abada**: **Eli Lilly and Company**: Current Employment, Current equity holder in publicly-traded company. **Balbas**: **Eli Lilly and Company**: Current Employment, Current equity holder in publicly-traded company. **Li**: **Eli Lilly and Company**: Current equity holder in publicly-traded company. **Ruppert**: **Telios Pharma**: Consultancy; **Eli Lilly and Company**: Current Employment, Current equity holder in publicly-traded company. **Jurczak**: **SOBI**: Research Funding; **AbbVie**: Consultancy; **Beigene**: Consultancy; **AstraZeneca**: Research Funding; **AbbVie**: Research Funding
Funding; Roche: Research Funding; Eli Lilly: Consultancy; BeiGene: Research Funding; Pfizer: Consultancy; AstraZeneca: Consultancy; Bayer: Research Funding; Takeda: Research Funding; Roche: Consultancy; SOBI: Consultancy; Takeda: Consultancy; Celgene: Research Funding; Pfizer: Consultancy; AstraZeneca: Consultancy; Bayer: Research Funding; Takeda: Research Funding; Wierda: Genentech: Research Funding; Juno Therapeutics: Research Funding; Sunesis: Research Funding; National Comprehensive Cancer Network: Other: Nonrelevant Financial Relationship/Chair, CLL). Supported by the NIH/NCI under award number P30 CA016672 and used MDACC Cancer Center Support Grant (CCSG) shared resources; Nurix Therapeutics: Research Funding; Pharmacyclics LLC: Research Funding; Gilead Sciences: Research Funding; AbbVie: Consultancy, Research Funding; Oncternal Therapeutics, Inc.: Research Funding; AstraZeneca/Acerta Pharma: Consultancy, Research Funding; Bristol Myers Squibb (Juno & Celgene): Consultancy, Research Funding; Cyclacel: Consultancy, Research Funding; Miragen: Research Funding; KITE Pharma: Research Funding; GlaxoSmithKline: Research Funding; Loxo Oncology, Inc./Lilly: Research Funding; Janssens Biotech: Research Funding; Janssens Biotech Inc: Research Funding; Numab Therapeutics: Research Funding; Accutar Biotechnology: Research Funding; NIH P30 CA016672/MDACC Cancer Center Support Grant: Research Funding; GSK/Novartis: Research Funding. OffLabel Disclosure: Pirtobrutinib is approved in the USA for treatment of relapsed or refractory MCL after at least 2 lines of systemic therapy, including prior BTKi.
631 Ibrutinib Plus Venetoclax with MRD-Directed Duration of Treatment Is Superior to FCR and Is a New Standard of Care for Previously Untreated CLL: Report of the Phase III UK NCRI FLAIR Study

Program: Oral and Poster Abstracts
Type: Oral
Session: 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Frontline Treatment With Targeted Agents in Patients With Chronic Lymphocytic Leukemia
Hematology Disease Topics & Pathways:
Lymphoid Leukemias, CLL, Combination therapy, Diseases, Therapies, Adverse Events, Lymphoid Malignancies, Minimal Residual Disease

Sunday, December 10, 2023: 4:30 PM

Peter Hillmen, MB ChB, PhD; David Allan Cairns, PhD; Adrian John Clifton Bloor, PhD, FRCPath, FRCP; David Allsup, MD; Kate Cwynarski, MBBS, PhD, FRCP, FRCPath; Andrew Pettitt, Shankaranarayana Paneesha, MD; Christopher P. Fox, MD, PhD, Toby A. Eyre, Francesco Forconi, MD, PhD, DM, FRCPath; Nagah Elmusharaf, Ben Kennedy, John G. Gribben, MD, DSc; Nicholas Pemberton, Oonagh Sheehy, Gavin Preston, PhD, MBBS, FRCP, FRCPath; Anna Schuh, MD, PhD, FRCP, FRCPath; Dena Howard, Anna Hockaday, Sharon Jackson, Natasha Greatorex, Sean Girvan, Sue Bell, Julia Brown, Nichola Webster, Surita Dalal, PhD; Ruth M de Tute, MSc, PhD, FRCPath; Andrew Rawstron, PhD; Piers EM Patten, FRCP, FRCPath, PhD and Talha Munir, MBBS, MRCP, FRCPath, PhD

1 Leeds Institute of Medical Research, St. James’s University Hospital, Leeds, United Kingdom
2 Leeds Institute of Clinical Trials Research, Cancer Research UK Clinical Trials Unit, Leeds, ENG, United Kingdom
3 Haematology and Transplant Unit, Christie NHS Foundation Trust, Manchester, United Kingdom
4 Castle Hill Hospital, Cottingham, GBR
5 University College London, London, United Kingdom
6 Royal Liverpool University Hospital, Liverpool, GBR
7 Birmingham Heartlands Hospital, Birmingham, United Kingdom
8 School of Medicine, University of Nottingham, Nottingham, United Kingdom
9 Churchill Hospital, Oxford University, Oxford, United Kingdom
10 Department of Haematology, Southampton University Hospital Trust, Southampton, United Kingdom
11 University Hospital of Wales, Cardiff, GBR
12 Leicester Royal Infirmary, Leicester, GBR
13 Barts Cancer Institute, Queen Mary University of London, London, United Kingdom
14 Worcestershire Acute Hospitals NHS Trust, Worcester, United Kingdom
Introduction: Ibrutinib (I), an irreversible Btk inhibitor, and venetoclax (V), a Bcl-2 inhibitor, improve CLL outcomes in trials compared to chemoimmunotherapy. I and V target two key pathophysiological pathways in CLL and should be synergistic. This is supported both by in vitro studies and Phase II trials in which I+V results in high proportions of measurable residual disease (MRD) negativity. A Phase III trial comparing I+V (15 months [mo]) with chlorambucil-obinutuzumab led to the approval of I+V. However, mathematical disease modelling and Phase II studies favor defining duration of I+V according to individual patient sensitivity. We hypothesized that I+V is more effective than FCR in CLL and that treatment duration personalised using MRD response would optimize outcome.

Methods: FLAIR (ISRCTN01844152) is a phase III, multicentre, randomised, controlled, open, parallel group trial for untreated CLL. Patients (pts) with ≥20% 17p deleted cells were excluded. FLAIR was adapted in 2017 to add 2 arms, I alone and I+V compared to FCR. Here we report the planned analysis of I+V vs FCR. In I+V after 2 mo I, V was added with a 4-week dose escalation to 400mg/day and then I+V for up to 6 years with duration of I+V defined by MRD (<1 CLL cell in 10,000 [flow cytometry]). PB MRD was assessed at 12 mo and then 6 monthly and if negative, was repeated at 3 mo and 6 mo in PB and BM. If all were MRD neg, then the duration of I+V was double the time between start of I+V and the initial MRD neg PB (I+V duration: 2 to 6 years). The primary endpoint for I+V vs FCR was investigator-assessed PFS. Key secondary endpoints presented were OS, IWCLL response, MRD and safety. Appropriate endpoints were analysed by CLL prognostic sub-groups.

Results: 523 pts were randomised to FCR (n=263) and I+V (n=260) at 96 UK Centers from 07/20/2017 to 03/24/2021. Data-lock on 05/23/2023. 71.3% male, median age 62 yrs (31.2% >65yo) and 40.9 % Binet Stage C. IGHV unmutated (≥98% homology to germline) in 56.9%, 37.6% IGHV mutated and 5.5% Subset 2. Hierarchical FISH: 20.6% 11q del, 20.1% trisomy 12, 27.8% normal and 31.4% 13q del. At 2 yrs 111/260 (42.7%)
and 3 yrs 135/232 (58.1%) pts stopped I+V according to the MRD stopping rules. At a median 43.7 months there were 87 progressions - 75 FCR and 12 I+V. The hazard ratio (HR) for PFS for I+V vs FCR is 0.13 (95% CI: [0.07, 0.24]; p<0.0001; Fig). This result was consistent for gender, age or stage. At 3 yrs 2.8% had progressed on I+V compared to 23.2% on FCR. There have been 34 deaths (25 FCR and 9 I+V) resulting in improved overall survival for I+V vs FCR: HR 0.31 (95% CI: [0.15, 0.67]; p=0.0029; Fig). At 3 years 2.0% of I+V pts had died compared to 7.0% for FCR. At 9 months (3 mo post-FCR) 48.3% FCR pts became MRD neg in BM compared to 41.5% for I+V. However, with continued I+V more pts became MRD neg: the odds of MRD negativity at any time for I+V vs FCR were 2.03 (95% CI: [1.43, 2.89]; P<0.001) in BM and 3.91 (95% CI: [2.55, 6.00]; P<0.001) in PB. 90.6% pts achieved PB MRD negativity at up to 5 yrs I+V and 88% of these were BM MRD negative 6 mo after their first PB MRD neg result. At 9 months a higher proportion achieved CR and overall response for I+V; CR – FCR 49.0% (95% CI: [42.9%, 55.3%]), I+V 59.2% (53%, 65.3%); ORR - FCR 76.4% (70.8%, 81.4%); I+V 86.5% (81.8%, 90.4%). This difference was greater for best response at any time: ORR 83.7% (78.6%, 87.9%) for FCR vs 95.4% (92.1%, 97.6%) for I+V; CR 71.5% (65.6%, 76.9%) for FCR vs 92.3% (88.4%, 95.2%) for I+V. The odds ratios estimate to achieve CR with I+V vs FCR is 1.51 (95% CI: [1.07, 2.14]; p<0.05). Responses and outcomes by FISH and IGHV will be presented. SAEs were reported in 252 (51.3%) pts (129 FCR vs 123 I+V). Notable SAEs by organ class for FCR vs I+V were: infections 18.8% of FCR pts vs 22.2% for I+V; blood and lymphatic 31% vs 5%; and cardiac in 0.4% vs 10.7%. 4 pts had sudden or cardiac deaths – 2 FCR and 2 I+V. 69 other cancers were diagnosed (45 in FCR, 24 in I+V) in 51 pts (34 FCR, 17 I+V). The incidence of other cancers per 100 pt-years was greater for FCR than I+V; 5.4 (95% CI: [5.11, 5.68]) vs. 2.6 (2.40, 2.79). There were 7 cases of MDS/AML with FCR and 1 with I+V.

Conclusion: Ibrutinib plus venetoclax significantly improved progression-free and overall survival compared to FCR in untreated CLL. Using MRD to direct the duration of I+V maximizes outcome with 97.2% progression free survival at 3 years The efficacy seen in FLAIR is superior to previous Phase III CLL trials indicating that I+V with duration guided by MRD is a new gold standard for CLL treatment.
Disclosures: Hillmen: Apellis Pharmaceuticals: Current Employment, Current equity holder in publicly-traded company. Cairns: Janssen: Honoraria; Celgene BMS: Honoraria, Research Funding; Sanofi: Research
Funding; Amgen: Research Funding; Takeda: Research Funding. **Bloor:** Abbvie: Consultancy, Honoraria, Speakers Bureau; Gilead, Janssen: Honoraria. **Cwynarski:** Abbvie: Membership on an entity’s Board of Directors or advisory committees; Roche, Takeda, Celgene, Atara, Gilead, KITE, Janssen, Incyte, Abbvie: Consultancy, Honoraria; Roche, Takeda, KITE, Gilead, Incyte: Speakers Bureau; Roche, Takeda, KITE, Janssen, BMS: Other: Conferences/Travel support. **Paneesha:** Gilead: Honoraria; Abbvie: Honoraria, Janssen: Honoraria; Astra Zeneca: Honoraria. **Fox:** AbbVie: Consultancy; Genmab: Consultancy, Membership on an entity’s Board of Directors or advisory committees. **Eyre:** Incyte: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; Loxo Oncology: Consultancy, Honoraria, Other, Speakers Bureau; Janssen: Consultancy, Honoraria, Speakers Bureau; Beigene: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding, Speakers Bureau; Autolus: Consultancy; Eli Lilly and Company: Consultancy, Honoraria, Speakers Bureau; KITE: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; Abbvie: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; Gilead: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; Loxo Lilly: Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; PeerView: Speakers Bureau; Medscape: Speakers Bureau; Secura Bio: Membership on an entity’s Board of Directors or advisory committees; AstraZeneca: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding, Speakers Bureau; Roche: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau. **Gribben:** AstraZeneca: Consultancy, Research Funding; AbbVie: Consultancy, Speakers Bureau; Kite, A Gilead Company: Consultancy, Speakers Bureau; Janssen Pharmaceuticals, Inc: Consultancy, Research Funding, Speakers Bureau; Novartis: Consultancy; Bristol Myers Squibb: Speakers Bureau. **Howard:** Roche: Current Employment. **Hockaday:** Abbvie: Speakers Bureau. **Rawstron:** Abbvie, BD Biosciences, Beckman Coulter, Beigene, Celgene, Gilead, Janssen, Pharmacyclics, Roche: Research Funding; Beigene, Pharmaceuticals: Consultancy; BD Biosciences: Patents & Royalties; Abbvie, Beigene, Innocare, Janssen, Medicxi, Thermo Fisher: Honoraria. **Patten:** Roche: Honoraria, Research Funding; Novartis: Honoraria; AbbVie: Honoraria, Other: Meeting Support; Astra Zeneca: Honoraria; Beigene: Honoraria, Other: Meeting Support; Kite / Gilead: Honoraria, Research Funding; Janssen: Honoraria, Other: Meeting Support. **Munir:** BeiGene: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; Abbvie: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding, Speakers Bureau; Alexion: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; Sobi: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau;
Bureau; Roche: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; AstraZeneca: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau.